

CURRICULUM VITAE

Prepared October 2009

DAVID HEALY, MD FRCPsych
C/O North Wales Department of Psychological Medicine
Hergest Unit, Ysbyty Gwynedd,
BANGOR,
Gwynedd LL57 2PW,
Wales (UK)
Tel: (1248) 384452
Fax: (1248) 371397
E-Mail: David.Healy54@googlemail.com

Citizenship: Republic of Ireland
Country of Residence: UK

APPOINTMENTS

November 2004 - Present	Professor of Psychiatry, Cardiff University
March 2004	Adjunct Professor in Centre for Social and Community Research Murdoch University, Perth, March 2004 – February 2007
April 2002/05	Visiting Professor, University of Toronto Faculty of Medicine
June 2000	Appointed Professor of Psychiatry, University of Toronto Head of the Mood & Anxiety Disorders Program.
Feb 1996	Reader in Psychological Medicine Division of Psychological Medicine, University of Wales College of Medicine (UWCM).
Feb 1992	Director, North Wales Department of Psychological Medicine (UWCM).
Jan 1990	Senior Lecturer in N Wales Dept of Psychological Medicine Division of Psychological Medicine University of Wales College of Medicine (UWCM), & Honorary Consultant in Psychiatry, Gwynedd

EDUCATION

Pre-Medical Education: Manor House School, Dublin, 1958-1960
St Fintan's High School, Dublin, 1961-1972
Belvedere College, Dublin, 1966-1972
Hons Leaving Certificate with Dept. Education Scholarship

Medical Education: University College Dublin, 1973-1979, MB BCh BAO
1st Medical Class Prize & Scholarship
MD (PhD in US) awarded in December 1986

Psychiatric Training: Member Royal College of Psychiatrists - Spring 1985
(Availed of the Membership Research Option)
Fellow Royal College of Psychiatrists - Spring 1996

PRE-MEMBERSHIP EXPERIENCE

July 1980 Research Fellow in Dept of Pharmacology,
University of Galway on MD thesis

Jan 1983 Senior House Officer, Dept of Psychiatry, Galway

July 1984 Registrar in St Patrick's Hospital, Dublin

July 1985 MD/PhD thesis write up.

POST-MEMBERSHIP EXPERIENCE

Jan 1986 Registrar St Mary's Hospital, Castlebar
April 1986. Clinical Research Associate, Dept of Psychiatry,
University of Cambridge Clinical School
& Honorary Senior Registrar

April 1988 Senior Registrar in Psychogeriatrics
with Drs C P B Brook and E Tym

May 1989 Locum Consultant Psychogeriatrician,
Fulbourn Hospital, Cambridge

Sept 1989 Senior Registrar in Adult Psychiatry in Norwich

Jan 1990 Locum Cons Norwich, responsible for Substance Abuse

RESEARCH TRAINING

MD thesis (this would be a PhD in the US) commenced August 1980,
Supervised by Brian Leonard, Prof. of Pharmacology, U College, Galway
& Directed by Professor T B Counihan, Dept of Medicine, U College, Dublin.
Thesis "Biochemical Correlates of Depression" submitted Dec 1985

A study of platelet 5HT uptake and 5HT induced aggregation responses, platelet alpha adrenoceptor binding and lymphocyte beta adrenoceptor binding in depression.

Clinical Research Associate - Dept of Psychiatry, Cambridge, April 86 - March 88

Funded by a Wellcome Trust Major Grant Award: Biological Markers in Depression.

My Cambridge research also included work on concentration & memory in depression

RESEARCH GRANTS

1. Research Fellowship Dept of Pharmacology, U Coll Galway, 1980-82.
2. MRC Ireland Research Grant to investigate circadian variations in biological markers in depression, 1982-1984.
3. Research Fellow 1986 to 1988; Wellcome Trust Major Grant Award held by Prof E S Paykel in Cambridge.
4. Grant holder from the Welsh Scheme for Health & Social Services Research for a Cognitive Therapy of Delusions, Jan 1992 to Jan 1994, £43,000.
5. Grant holder Clwyd H.A.: Cognitive Therapy of Delusions; £50,000.
6. Grant holder Wellcome Trust for equipment for investigating the cognitive neuropsychology of neuroleptic drugs. £5,000.
7. Grant holder SmithKline Beecham for work on the cognitive neuropsychology of drugs active on the 5HT system. £50,000.
8. Clinical trial of a 5HT-1A agonist in depression, Duphar, £25,000.
9. Co-Holder of a MRC/Welsh Office/NW Reg H Authority Grant with R Bentall, R Stevenson and J Day (U of Liverpool), A Rogers (U of Manchester) G9322371, A multidisciplinary study of the management of neuroleptic medication in schizophrenia: educational and collaborative approaches. 1994-1998, £300,000.
10. Collaborator with M Jones and P Michael (UWB) on a Wellcome Trust Grant to research the history of the North Wales Hospital 1992-1995.
11. Co-holder Wellcome Trust Grant with Dr M Fraser and Professor N Rose, Dept of Sociology, Goldsmith's College London, Ethical Aspects of Psychiatric Drug Development, £88,000. Grant no. 065209/Z/01/Z/CM/CD/SW, 2001-2004.
12. Co-holder with Professor E Shorter, Dept of History, U of Toronto, of a Canadian Institutes of Health Research grant 116654: "The renewal of the pharmacopoeia for mood and anxiety 1966-2003", \$312,000: 1.10.03 to 30.09.06.
13. Coholder with Mark Rapley: Medicating the Unruly Child: A genealogy of ADHD, = \$AUS18, 500, MU Research Excellence Grants Scheme, no #.
14. Coholder with F Bayliss, J Downey et al The Ethics of Neuroscience, Canadian Institutes of Health Research. Granted Spring 2006.
15. Holder grant on Toxoplasmosis infection in psychosis from Stanley Medical Research Foundation, granted Summer 2007, \$300,000.

ROYAL COLLEGE of PSYCHIATRISTS ACTIVITIES

Senior Organiser MRCPsych exam 1991-1993
Scheme Organiser for Senior/Specialist Registrars 1992-1997.
MRCPsych Part I examiner
College representative on Appointment Committees
Assessor of Membership Research Projects

MEMBERSHIP OF SOCIETIES

Royal College of Psychiatrists - 1985.
Fellow - 1996.
British Association of Psychopharmacology -
Council Member & Hon Asst Secretary, 1989-1992
Secretary 1992-1995
Member of the Association of European Psychiatrists.
Member of European College of Neuropsychopharmacology
Fellow of Collegium Internationale Neuropsychopharmacologium
Member of the History Group Royal College of Psychiatrists
Member of the European Association for the History of Psychiatry
Member of the History Section of the World Psychiatric Association
Secretary 2009 ongoing.
Member of the European Society for Chronobiology
Member Advisory Board of European College of Study Methods in Clinical Trials
Member of ECNP working party for the History of Neuropsychopharmacology
Associate of BIOS: Centre for the study of Bioscience, Biomedicine, Biotechnology and Society at the London School of Economics and Political Science

DISTINCTIONS

- First Mental Health Foundation Essay Prize for 1988
- Awarded a CIMP Rafaelson Scholar Award in 1988
- Keynote Speaker at 30th Annual RANZCP Meeting - May 1995.
- Visiting Lecturer at the Clarke Institute of Psychiatry & Guest Lecturer on the History of Medicine Program, Univ. of Toronto, October 1995.
- Chair Wellcome Trust Witness Seminar March 1997.
- Guest Lecturer. 7th Japanese Clin Neuropharmacology Assoc. Tokyo, Nov 1997.
- Invited Lecture – American Psychopathological Association March 1999.
- Annual Raths-Steiger Lecture, Collegium Helveticum, ETH Zurich June 1999.
- Distinguished Guest Lecture, Dept of Psychiatry, Oslo, March 2000.
- Eric T Carlsson Memorial Grand Rounds, Cornell University, N York, Dec 2000
- Annual MIND-Institute of Psychiatry Lecture, February 2002.
- Bartlett Visiting Professorship, U of Rochester, N York, Nov 2003.
- Studium Generale Lecture Groningen April 2005
- Chancellor's Distinguished Guest Lecture, Louisiana State University Oct 2005
- ACNP Oakley Ray Annual Lecture on History of Psychopharmacology 2008

BOOKS

THE SUSPENDED REVOLUTION
Psychiatry and Psychotherapy Re-examined
Faber & Faber, January 1990

IMAGES OF TRAUMA
From Hysteria to Post-traumatic Stress Disorder
Faber & Faber, March 1993

PSYCHIATRIC DRUGS: EXPLAINED.
Mosby Yearbooks Ltd, March 1993
Second Edition Harcourt Brace & Jovanovitch Winter 1996
Third Edition Churchill Livingstone 2001
Fourth Edition Elsevier Churchill Livingstone 2005
Fifth Edition 2008.
Japanese & French Translations 2009

PSYCHOTROPIC DRUG DEVELOPMENT:
Social, Economic and Pharmacological Aspects
A British Association for Psychopharmacology Monograph
Chapman and Hall, Spring 1996
Co-Editors: D Healy, D Doogan

THE PSYCHOPHARMACOLOGISTS
Chapman & Hall, London, 1996
Second Edition, Arnold, London, 2002

THE ANTIDEPRESSANT ERA
Harvard University Press, Cambridge Mass, 1997
Paperback Edition 1999
French Translation – Le Temps des Antidepresseurs, 2002.
Japanese Translation 2003
Spanish Translation Forthcoming

THE PSYCHOPHARMACOLOGISTS (Vol 2)
Chapman & Hall, London, 1998
Second Edition, Arnold, London 1999.

THE PSYCHOPHARMACOLOGISTS (Vol 3)
Arnold, London (2000)
With a reissue of Volumes 1 & 2.

**THE RISE OF PSYCHOPHARMACOLOGY
& THE STORY OF THE CINP**

Animula, 1998

Co-Editors: T Ban, D Healy, E Shorter

**TEN YEARS THAT CHANGED THE FACE OF MENTAL ILLNESS
(LES DIX ANS QUI ONT CHANGÉ LA FOLIE)**

Martin Dunitz, London 1999

Jean Thuillier

Translated from the French by Gordon Hickish & David Healy

DIFFERENTIAL EFFECTS of The ANTIDEPRESSANTS

Leonard BE, Healy D (1999).

Martin Dunitz, London.

British Medical Association Book Prize;

Mental Health Section – Highly Commended.

Translated into Spanish (2000).

THE TRIUMPH OF PSYCHOPHARMACOLOGY AND THE CINP.

Ed Ban T, Healy D, Shorter (2000).

Animula, Budapest.

THE CREATION OF PSYCHOPHARMACOLOGY

Harvard University Press,

Cambridge Mass 2002.

Paperback Edition, 2004

**FROM PSYCHOPHARMACOLOGY TO NEUROPSYCHOPHARMACOLOGY
& THE STORY OF THE CINP**

Ed Ban T, Healy D, Shorter E (2002)

Animula, Budapest

LET THEM EAT PROZAC

David Healy (2003)

James Lorimer, Toronto

With linked website www.healyprozac.com

Second Edition New York University Press (2004)

Japanese Translation 2005

Paperback Edition 2006

CLINICAL PSYCHIATRY in EUROPE

An Historical Perspective

from Selected Papers by Pierre Deniker

Translated by David Healy & Alden Press (2004)

Royal Society of Medicine Press, London

EUROPEAN CLINICAL PSYCHIATRY
An Historical Perspective
from Selected Scientific Papers by Pierre Deniker
Translated by David Healy & Alden Press (2007)
Pierre Deniker Association, www.association-pierre-deniker.org Paris

REFLECTIONS ON TWENTIETH CENTURY
PSYCHOPHARMACOLOGY
Ed T Ban, D Healy, E Shorter
Animula Press, Budapest, 2004

SHOCK THERAPY:
A History of Electroconvulsive Treatment in Mental Illness
E Shorter and D Healy
Rutgers University Press
University of Toronto Press
September 2007

MANIA
A Short History of Bipolar Disorder
Johns Hopkins University Press
Spring 2008

TRAITÉ MÉDICO-PHILOSOPHIQUE SUR L'ALIÉNATION MENTALE
Philippe Pinel
Translated G Hickish, D Healy, L Charland
J Wiley & Sons 2008

Books in Progress

PHARMAGEDDON

This book covers aspects of the history of medicine and its changing culture over the past century, and in particular the rise of quantification and the impact of this on the practice and understanding of medicine. The book is written. I am hoping for a trade publisher.

THE GARDEN OF GOOD & EVIL

This book centers on the recent legal battles over the prenatal use of antidepressants. This has led to a jury trial in Sept 2009, at which I was the first expert witness. The trial resulted in a verdict for the plaintiff. The larger issues concern the abilities of pharmaceutical companies to change cultures so that what would recently have been clinically inconceivable becomes a clinical norm, and also the role of women within medicine as both patients and deliverers of healthcare. This book at present is part written.

PEER- REVIEWED JOURNAL PUBLICATIONS

Principal Author = PA

Co-Principal Author = CPA

Collaborator = C

D = Data article; OH = Original Hypothesis; R = Review Article

1. Healy D, Dunne M, Duignan J & Heffernan S J (1980). The use of ultrasonography in the diagnosis of retroperitoneal abscesses of the appendix. *Irish J of Medical Science*, 149, 479 (CPA - D).
2. Healy D, Carney PA & Leonard BE (1983). Monoamine- related markers of depression: change following treatment. *Journal of Psychiatric Research*, 17, 251-260 (CPA - D).
3. Carney P A, Healy D, Leonard B E (1984). A double-blind study to compare trazodone with amitriptyline in depressed patients. *Psychopathology* 17, supp 2, 37-38 (CPA - D).
4. Healy, D, Carney, P A & Leonard, B E (1984). Biochemical correlates of antidepressant response. *Psychopathology*, 17, supp 2, 82-87 (CPA - D).
5. Healy, D, Carney, P A & Leonard, B E (1984). 5HT induced platelet aggregation, a useful clinical index in depression? *British Journal of Clinical Pharmacology*, 17, 202-203p (CPA - D).
6. Healy D & Egan E (1984). Centrifugal and anticoagulant induced variations on platelet rich plasma and their influence on platelet aggregation. *Scandinavian Journal of Haematology*, 32, 452-456 (CPA - D).
7. Healy D, O'Halloran A, Carney PA & Leonard, BE (1985). Peripheral adrenoceptors and serotonin receptors: changes associated with response to treatment with trazodone or amitriptyline. *Journal of Affective Disorders*, 9, 285-296 (CPA - D).
8. Healy D, O'Halloran A, Carney PA & Leonard BE (1986). Normal and abnormal variation in platelet 5HT uptake in control and depressed patients. *Journal of Psychiatric Research*, 20, 345-354 (PA - D).
9. Healy D, O'Halloran A, Carney PA & Leonard BE (1986). Platelet 5HT uptake in delusional and nondelusional depression. *J Affective Disorders*, 10, 233-239 (PA).
10. Healy D, O'Halloran A & Leonard B E (1986). Increases in platelet 5HT uptake rates following treatment with "uptake inhibiting drugs". *International Clinical Psychopharmacology*, 1, 332-339 (PA - D).

11. Healy D (1986). Platelet monoamine uptake in depression: both chicken and egg deserve attention. *Human Psychopharmacology* 1, 48-49 (PA - R).
12. Healy D & Leonard BE (1987). Monoamine transport in depression: kinetics and dynamics. *Journal of Affective Disorders* 12: 91-105 (PA - R).
13. Healy D (1987). The structure of psychopharmacological revolutions. *Psychiatric Developments*, 5, 349-376 (PA - OH).
14. Healy D (1987). Rhythm and Blues: neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders. *Psychopharmacology*: 93, 271-285 (PA - OH).
15. Healy D (1987). The comparative psychopathology of animal and human affective disorders. *Journal of Psychopharmacology*, 1, 193-210 (PA - R).
16. Healy D & Williams JMG (1988). Dysrhythmia, dysphoria and depression; the interaction of circadian dysrhythmia and learned helplessness in the pathogenesis of depression. *Psychological Bulletin* 103: 163-210 (PA - OH).
17. Healy D (1988). Neuropsychopharmacology - gazing into the crystal ball; a reply to Arvid Carlsson. *Human Psychopharmacology*, 3, 221-223 (PA - R)
18. Healy D & Williams JMG (1989). Moods, misattributions and mania: an interaction of cognitive and neurobiological factors in the pathogenesis of mania. *Psychiatric Developments*, 7, 49-70 (PA - OH).
19. Healy D (1989). Neuroleptics and psychic indifference. *Journal of the Royal Society of Medicine*, 82, 615-619 (PA - OH).
20. Williams JMG, Healy D, Teasdale J, White W, Paykel ES (1990). Dysfunctional attitudes and vulnerability to persistent depression. *Psychological Medicine*, 20, 375-381 (CPA - D).
21. Healy D, Waterhouse JM (1990). The circadian system and affective disorders: clocks and rhythms. With peer commentary by T Wehr, A Lewy . *Chronobiology International*, 7, 5-24 (CPA - OH).
22. Healy D (1990). Schizophrenia: basic, release, reactive and defect processes. *Human Psychopharmacology*, 5, 105-122 (PA - R).
23. Watts FN, Dalgleish T, Bourke P, Healy D (1990). Memory deficit in clinical depression: processing resources and structure of material. *Psychological Medicine*, 20, 345-349 (CPA - D).

24. Healy, D, Theodorou, A, Whitehouse, A M, White, W, Wilton- Cox, H, Lawrence, K M, Kerry, S, Horton, R W, Paykel, E S (1990). Tritiated imipramine binding to previously frozen platelet membranes from depressed patients before and after treatment. *British Journal of Psychiatry* 157, 208-218 (CPA - D).
25. Healy D, Paykel ES, White W, Whitehouse AM, Wilton-Cox H, Johnson T, Lawrence KM, Horton RW (1991). Platelet 3H Imipramine and alpha 2 adrenoceptor binding in normal subjects taking desipramine. *Neuropsychopharmacology* 4, 117-124 (CPA – D).
26. Healy, D, (1990). The psychopharmacological era: notes toward a history. *Journal of Psychopharmacology* 4, 152-167 (PA - OH).
27. Healy, D & Waterhouse J M (1991). Reactive rhythms and endogenous clocks: a shift work model of affective disorders. *Psychological Medicine* 21, 557-564 (CPA - OH).
28. Healy, D, Paykel, E S, Whitehouse, A M, White W, Ashby M, Brown M, Theodorou A E, Lawrence, K M, Horton, R W (1992). Plasma noradrenaline, adrenaline and DHPG responses to clonidine in control and depressed subjects. *Human Psychopharmacology* 7, 167-174 (CPA - D).
29. Healy, D, Paykel, E S, White, W, Whitehouse, A M, Wilton- Cox, H, Theodorou A E Lawrence, K M, Horton, R W (1991). Acid alpha-1 glycoprotein in eating disorders and depression. *Journal of Affective Disorders* 22, 13-20 (PA - D).
30. Theodorou A E, Lawrence K M, Healy, D, Whitehouse, A M, White W, Wilton-Cox, H, Kerry S M, Horton, R W Paykel E S (1991). Platelet alpha-2-adrenoceptors defined with agonist and antagonist ligands in depressed patients prior to and following treatment. *Journal of Affective Disorders* 23; 99-106 (CPA - D).
31. Healy D (1991). The marketing of 5HT: anxiety or depression. *British Journal of Psychiatry*, 158, 737-742 (PA - OH).
32. Healy D (1991). What do 5HT reuptake inhibitors do in obsessive-compulsive disorder. *Human Psychopharmacology*, 6, 325-328 (PA - OH).
33. Creaney W, Murray I, Healy D (1991). Antidepressant induced suicidal ideation. *Human Psychopharmacology*, 6, 329-332 (PA - D).
34. Healy D (1991). D-1 and D-2 and D-3. *British J of Psychiatry* 159, 319-324 (PA - OH).
35. Healy D (1991). The ethics of psychopharmacology. *Changes*, 9, 234-247 (PA - R).

36. Healy D (1991). Alprazolam and panic disorder. *Psychiatric Bulletin* 15, 682-683 (PA - R).
37. Browne I & Healy D (1992). In Conversation with Ivor Browne. *Psychiatric Bulletin* 16, 1-9 (CPA - D).
38. McGrath D & Healy D (1992). In Conversation with Des McGrath. *Psychiatric Bulletin* 16, 129-137 (CPA - D).
39. Katona C L E, Healy D, Paykel E S, Theodorou A E, Lawrence K M, Whitehouse A M, White W, Horton R W (1993). Growth hormone and physiological responses to clonidine in depression. *Psychological Medicine* 23, 57-63 (CPA - D).
40. Healy D (1993). Psychopharmacology and the ethics of resource allocation. *British Journal of Psychiatry* 162; 23-29 (PA - OH).
41. Healy D (1992). Altered states of consciousness: Phenomenology and pharmacology. *Journal of Psychopharmacology* 6, 425- 435 (PA - R).
42. Healy D (1993). One hundred years of psychopharmacology. *Journal of Psychopharmacology* 7, 207-214 (PA - R).
43. Healy D, Minors D, Waterhouse J M (1993). Shiftwork, helplessness and depression. *Journal of Affective Disorders* 29, 17- 25 (PA - D).
44. Moore J N P, Healy D, (1993). Interview with Norman Moore. *Irish Bulletin of Psychiatry* 1, 7-16 (PA - D).
45. Healy D (1993). 5HT and physical illness. *Journal of Psychopharmacology* 7, suppl. 1, pp 107-111 (PA - R).
46. Beaumont G, Healy D (1993). The place of clomipramine in the history of psychopharmacology. *Journal of Psychopharmacology* 7, 378-388 (CPA - D).
47. Minors D, Healy D, Waterhouse J M (1994). The attitudes and general health of student nurses before and immediately after their first eight weeks of nightwork. *Ergonomics* 37, 1355-1362 (C - D).
48. Sandler M, Healy D (1994). The Place of Chemical Pathology in the development of Psychopharmacology. *J of Psychopharmacology* 8, 124-133 (CPA - D).

49. Watson F L, Pasteur M A, Healy D, Hughes E A (1994). Nine Parallel versions of four memory tests: An assessment of form equivalence and the effects of practice on performance. *Human Psychopharmacology* 9, 51-61 (C - D).
50. Healy D (1994). The fluoxetine and suicide controversy. *CNS Drugs* 1 223-231 (PA - R).
51. Claridge G, Healy D (1994). The psychopharmacology of individual differences. *Human Psychopharmacology* 9, 285-298 (CPA - D).
52. Wheatley D, Healy (1994). The foundation of the British Association for Psychopharmacology. *J Psychopharmacology* 8, 268-278 (CPA - D).
53. Healy D, Waterhouse J M (1995). The circadian system and the therapeutics of the affective disorders. *Pharmacology and Therapeutics* 65, 241-263 (CPA - R).
54. Fear C, Sharp H, Healy D (1995). Obsessive-compulsive disorder: Notes on its History and Nosology. *Journal of Serotonin Research* 1, Suppl 1, 1-18 (PA - R).
55. Fitzgerald K, Healy D (1995). Dystonias and dyskinesias of the jaw associated with the use of SSRIs. *Human Psychopharmacology* 10, 215-220 (PA - D).
56. Fear C, Sharp H, Healy D (1996). Cognitive processes in Delusional Disorders. *Brit J Psychiatry* 168, 61-67 (CPA - D).
57. Healy D (1995). Social Phobia. *Primary Care Psychiatry* 1, 31-38 (PA - R).
58. Fitzgerald K, Williams B, Healy D (1997). Shared Care? Some effects of patient access to medical communications. *Journal of Mental Health* 6, 37-46 (CPA - D).
59. Sharp H M, Fear C F, Williams, J M G, Healy D, Lowe C F, Yeadon H, Holden R (1996). Delusional phenomenology: Dimensions of change. *Behaviour Research and Therapy* 34, 123-142 (CPA - D).
60. Minors D S, Pirmohamed J, Williams G, Edwards R, Healy D, Waterhouse J. (1995). Circadian rhythms of activity and rectal temperature at home and in hospital: the effects of lifestyle. *Chronobiology International* 12, 199-205 (C - D).
61. Richter D, Healy D (1995). The origins of mental health-oriented neuroscience in Britain. *Journal of Psychopharmacology* 9, 392-399 (CPA - D).
62. Adeniran R, Healy D, Sharp HM, Williams J M G Minors D S, Waterhouse J M (1996). Interpersonal sensitivity predicts depressive symptom response to the

- circadian rhythm disruption of night work. *Psychological Medicine* 26, 1211-1221 (PA - D).
63. Harborne G C, Watson F L, Healy D, Groves L (1996). The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. *Journal of Psychopharmacology* 10, 134-140 (CPA - D).
64. Rees W L, Healy D (1997). The Place of Clinical Trials in the Evolution of Psychopharmacology. *History of Psychiatry*, 8, 1-20 (CPA - D).
65. Fear C, Healy D (1997). Probabilistic reasoning in obsessive-compulsive and delusional disorders. *Psychological Medicine* 27, 199-208 (CPA - D).
66. Fear C F, Healy D (1996). The use of the Emotional Stroop Test to assess neuroleptic activity. *Human Psychopharmacology* 11, 373-377 (CPA - D).
67. Sharp H, Fear C F, Healy D (1997). Attributional style and delusions: An investigation based on delusional content. *European Psychiatry* 12, 1-7 (CPA - D).
68. Sharp H M, Healy D, Fear C F (1998). Symptoms or side-effects? Methodological hazards and therapeutic principles. *Human Psychopharmacology* 13, 467-475 (CPA - D).
69. Healy D (1998). Meta-analysis of trials comparing antidepressants and active placebos. *British Journal of Psychiatry* 172, 232-234 (PA - R).
70. Fear CF, McMonagle T, Healy D (1998). Delusional Disorders. Boundaries of a Concept. *European Psychiatry* 13, 210-218 (commentaries by P Pichot and H-J Moller and colleagues) (PA - R).
71. Healy D, Farquhar G (1998). The immediate effects of droperidol. *Human Psychopharmacology* 13, 113-120 (PA - D).
72. Williams B, Coyle J, Healy D (1998). The meaning of patient satisfaction. An explanation of high reported levels. *Social Science & Medicine* 47, 1351-1360 (C - D).
73. Rogers A, Day JC, Williams B, Randall F, Wood P, Healy D, Bentall RP (1998). The meaning and management of neuroleptic medication; A study of patients with schizophrenia. *Social Science & Medicine* 47, 1313-1323 (C - D)
74. Healy D, Mc Monagle TM (1997). Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. *J Psychopharmacology* 11, S25-S31 (PA-R).

75. Healy D, Nutt D (1997). British Association for Psychopharmacology Consensus on Statement on Childhood and Learning Disabilities Psychopharmacology. *J Psychopharmacology* 11, 291-294 (SRA - R).
76. Tranter R, Healy D (1998). Neuroleptic discontinuation syndromes. *Journal of Psychopharmacology* 12, 306-311 (PA - OH).
77. Healy D, Savage M (1998). Reserpine Exhumed. *British J Psychiatry* 172, 376-378 (PA - R).
78. Healy D, Langmaak C, Savage M (1999). Suicide in the Course of the Treatment of Depression. *Journal of Psychopharmacology* 13, 94-99. (PA - OH).
79. Healy D (1998). Reboxetine, fluoxetine and social functioning as an outcome measure in antidepressant trials: implications. *Primary Care Psychiatry* 4, 81-89 (PA - R).
80. Healy D, Nutt D (1998). Prescriptions, licenses and evidence. *Psychiatric Bulletin* 22, 680-684 (PA - OH).
81. Healy D, Tranter R (1999). Pharmacologic Stress Diathesis Syndromes. *J Psychopharmacology* 13, 287-290; with commentaries by H Ashton, A Young and N Ferrier, R Baldessarini, A Viguera and L Tondo, L Hollister, P Haddad and I Anderson, P Tyrer, pp 291-298 & Reply by Healy D & Tranter R – In the shadow of the benzodiazepines p 299 (PA - R).
82. Healy D (1999). Guest Editorial: A Failure to Warn. *International Journal of Risk & Safety in Medicine* 12, 151-156 (PA - OH).
83. Healy D (1999). Reboxetine's effects on a social adaptation self-evaluation scale. *Acta Psychiatrica Scandinavia* 101, suppl 402, 45-51 (PA - D).
84. Healy D (1998). Pioneers in Psychopharmacology. *International Journal of Neuropsychopharmacology* 1, 191-194 (PA - R).
85. Healy D, Healy H (1998). The clinical pharmacological profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing? *Journal of Affective Disorders* 51, 313-322 (PA - R).
86. Healy D (1999). The Three Faces of the Antidepressants. *Critical Comments on the Clinical-Economic Framework of Diagnosis. J Nervous & Mental Disease* 187, 174-180 (PA - OH).
87. Healy D (1999). Antidepressant psychopharmacotherapy: at the crossroads. *International Journal of Psychiatry in Clinical Practice* 3, S9-S15 (PA - R).

88. Healy D (1999). Clinical trials and legal jeopardy. *Bulletin of Medical Ethics* 153, 13-18 (PA – OH).
89. Fear C F, Sharp H M, Healy D (2000). Obsessive-compulsive disorder with delusions. *Psychopathology* 33, 55-61 (CPA - D).
90. Healy D (2000). Some continuities and discontinuities in the history of the physical therapies before and after chlorpromazine. *History of Psychiatry* 11, 393-412 (PA – OH).
91. Healy D (2000). A Dance to the Music of the Century. *Psychiatric Bulletin* 24, 1-3 (PA – R).
92. Healy D (2000). Good Science or Good Business? *Hastings Center Report* 30, 19-23. One of a series of 5 articles on aspects of the Prozac phenomenon with Carl Elliott, Peter Kramer, James Edwards and David DeGrazia (PA - OH).

Republished in *Zlatna Greda* 14, pp 6-9, with commentary on the circumstances surrounding publication.
93. Healy D (2000). The case for an individual approach to the treatment of depression. *Journal of Clinical Psychiatry* 61, supplement 6, 24-28 (PA – R).
94. Healy D (2000). The assessment of outcome in depression. Measures of social functioning. *Reviews in Contemporary Pharmacotherapy* 11, 295-301 (PA – R).
95. Healy D (2000). Antidepressant induced suicidality. *Primary Care Psychiatry* 6, 23-28 (PA – D).
96. Healy D (2000). Pioneers in Psychopharmacology II. *International Journal of Neuropsychopharmacology* 3, 351-354 (PA – R).
97. Healy D (2001). Evidence biased psychiatry. *Psychiatric Bulletin* 25, 290-291 (PA – R).
98. Healy D, Savage M, Michael P, Harris M, Hirst D, Carter M, Cattell D, McMonagle T, Sohler N, Susser E (2001). Psychiatric bed utilisation: 1896 and 1996 compared. *Psychological Medicine* 31, 779-790 (CPA - D).
99. Williams B, Healy D (2001). Perceptions of illness causation among new referrals to a community mental health team: “explanatory model” or “exploratory map”. *Social Science & Medicine* 53, 465-476 (C - D).
100. Boardman A, Healy D (2001). Modeling suicide risk in affective disorders. *European Psychiatry* 16, 400-405 (CPA – D).

101. Williams B, Healy D (2001). Development of an explanatory model for “minor” mental health problems. *Journal of Advanced Nursing* 35, 108-116 (C - D).
102. Healy D (2001). The dilemmas posed by new and fashionable treatments. *Advances in Psychiatric Therapy* 7, 322-327 (PA – OH).
103. Healy D (2001). Psychopharmacology and the Government of the Self.
A) Nature, Medicine, Website publication complete with slides, 28th June.
B) This has also appeared on AcademyAnalyticArts.org.
C) This has been translated as Psicofarmacologia y dominacion del ego, and appeared complete with slides in the periodical La Insignia, at www.insignia.org/2003/enero/cyt_001.htm
D) Also published in The Rights Tenet, Spring 2002, pages 6-20 &
E) In Misuzu (Japanese) in November 2004, pp 18-32.
F) Trajectory in Psychopharmacology: The role of the clinician and industry.
Indian Journal of Psychiatry 2003, 45, 49-56,
with response from H Meltzer p 57 and J Kane p 58.
G) La Psychopharmacologie et le Gouvernement de Soi. In *Psythère. Revue de Psychiatrie*. www.psythere.free.fr//article.php?id_article=39 posted 15/06/2005.
104. Tranter R, Healy H, Cattell D, Healy D (2002). Functional variations in agents differentially selective to monoaminergic systems. *Psychological Medicine* 32, 517-524 (CPA – D).
105. Healy D (2002). Conflicting interests in Toronto. Anatomy of a Controversy at the Interface of Academia and Industry. *Perspectives in Biology & Medicine* 45, 250-263 (PA – D).
106. Herxheimer A, Healy D (2002). Arrhythmias and sudden death in patients taking antipsychotic drugs. *British Medical Journal* 325, 1253-1254.
107. Healy D (2002). Mandel Cohen and the Origins of the Diagnostic and Statistical Manual, Third Edition: DSM-III. *History of Psychiatry* 13, 209-230 (PA – D).
108. Foster J, Finlayson S, Bentall R, Day J, Randall F, Wood P, Reid D, Rogers A, Healy D (2003). The perceived expressed emotion in staff scale. *Journal of Psychiatric and Mental Health Nursing* 10,109-117.
109. Harris M, Chandran S, Chakroborty N, Healy D (2003). Mood stabilizers: the archaeology of the concept. *Bipolar Disorders* 5, 446-452, with commentary by Paul Grof.

110. Healy D, Thase M (2003). Is academic psychiatry for sale? *British J Psychiatry* 182, 1-3.
111. Healy D (2003). Lines of Evidence on SSRIs and Risk of Suicide. *Psychotherapy and Psychosomatics* 72, 71-79. (PA – D).
112. Healy D, Cattell D (2003). The Interface between authorship, industry and science in the domain of therapeutics. *British Journal of Psychiatry* 182, 22-27 (PA – D).
113. Healy D, Whitaker CJ. (2003) Antidepressants and suicide; Risk-Benefit Conundrums. *J Psychiatry & Neuroscience* 28 (5) 331-339, with response by Y Lapierre 340-349 (PA – D).
114. Healy D (2003). In the grip of the python: conflicts at the university-industry interface. *Science and Engineering Ethics, Special Issue Ethical Issues in Research Relationships at the University Industry Interface* (PA- R). 9, 59-72.
115. Healy D (2003). Psychopharmacology 102. What they neglected to mention in psychopharmacology 101. *The Clinical Psychologist* 56, 10-27. With commentaries by D Antonuccio & W Danton, I Kirsch, R Levant & M Sammons, M Mavissakalian, and Michael Thase (PA – R).
116. Healy D (2004). Shaping the Intimate. Influences on the Experience of Everyday Nerves. *Social Studies of Science* 34, 219-245 (PA).
117. Healy D (2004). Conflicting Interests: The evolution of an issue. *Monash Review of Bioethics* 23, 8-18 (PA - R).
118. Healy D (2004). Perspective. Manufacturing Consensus. *Hasting Center Reports* July-August, 53 (PA).
119. Healy D (2004). Psychopharmacologie et Histoire: Un Manifeste. *Psychiatrie, Sciences Humaines et Neurosciences* 2, 3-7 (PA - R).
120. Healy D, Harris M, Cattell D, Michael P, Chalasanni P, Hirst D (2005). Service Utilisation in 1896 and 1996: Morbidity and Mortality data from North Wales. *History of Psychiatry* 16, 27-41 (CPA – D)
121. Chalassani P, Healy D, Morriss R (2005). Presentation and frequency of catatonia in new admissions to two acute psychiatric admission units in India and Wales. *Psychological Medicine* 35, 1667-1675 (CPA – D).
122. Harris M, Chandran S, Chakroborty N, Healy D (2005). Service Utilization in Bipolar Disorder, 1890 and 1990 compared. *History of Psychiatry* 16, 423-434.

123. Fergusson D, Doucette S, Cranley-Glass K, Shapiro S, Healy D, Hebert P, Hutton B (2005). The association between suicide attempts and SSRIs: A systematic review of 677 randomized controlled trials representing 85,470 participants. *British Medical Journal* 330, 396-399 (C – D).
124. Healy D, Aldred G (2005). Antidepressant drug use and the risk of suicide. *International Review of Psychiatry* 17, 163-172 (CPA – D).
125. Day JC, Bentall RP, Roberts D, Randall F, Rogers A, Cattell D, Healy D, Rae P, Power C (2005). Attitudes towards antipsychotic medication. The impact of clinical variables and relationships with health professionals. *Arch Gen Psychiatry* 62, 717-724.
126. Healy D (2005). Contra Pfizer. *Ethical Human Psychology & Psychiatry* 7, 181-195.
127. Healy D, Herxheimer A, Menkes D (2006). Antidepressants and violence: Problems at the interface of medicine and law. (CPA – D). *PLoS Medicine* 3, Sept, DOI: 10.1371/journal.pmed.0030372
128. Healy D, Herxheimer A, Menkes D (2007). Antidepressants and violence: Problems at the interface of medicine and law. *Int J Risk & Safety Medicine* 19, 17-33.
129. Healy D (2006). Manufacturing Consensus. *Culture, Medicine and Psychiatry* 30, 135-156. DOI 10.1007/s11013-006-9013-3
130. Healy D (2006). The Antidepressant Tale: Figures Signifying Nothing? *Advances in Psychiatric Treatment* 12, 320-328. Commentary by J Geddes.
131. Healy D (2006). Neuroleptics and mortality: a 50-year cycle. *British Journal of Psychiatry* 188, 128.
132. Healy D, Harris M, Tranter R, Gutting P, Austin R, Jones-Edwards G, Roberts AP (2006). Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. *British Journal of Psychiatry* 188, 223-228 (PA – D). With Commentary by T Turner, 229-230.
133. Healy D (2006). Did regulators fail over selective serotonin reuptake inhibitors. *BMJ* 333, 92-95.
134. Healy D (2006). The Latest Mania. Selling Bipolar Disorder. *PLoS Medicine*. <http://dx.doi.org/10.1371/journal.pmed.0030185>

135. Tschinkel S, Harris M, Le Noury J, Healy D (2007). Postpartum Psychosis: Two Cohorts Compared, 1875-1924 & 1994 – 2005. *Psychological Medicine* 37, 529-536. doi:10/1017/S0033291706009202.
136. Farquhar F, Le Noury J, Tschinkel S, Harris M, Kurien R, Healy D (2007). The incidence and prevalence of manic-melancholic syndromes in North West Wales: 1875-2005. *Acta Psychiatrica Scandinavia* 115, (suppl 433), 37-43.
137. Healy D (2007). The New Engineers of Human Souls and Academia. *Epidemiologia e Psichiatria Sociale* 16. 205-211.
138. Healy D, Le Noury J (2007). Paediatric Bipolar Disorder. An object of study in the creation of an illness. *Int J Risk & Safety in Medicine* 19, 209-221.
139. Healy D (2007). The New Anecdotes. *Ethical Human Psychology and Psychiatry* 9, 131-137.
140. Healy D, Savage M, Tranter R, Austin R, Ijaz Q, Hughes JA, Oberholzer D, Gutting P, Roberts AP (2007). Guidelines, Tramlines, and Faultlines. *Ethical Human Psychology and Psychiatry* 9, 238-244.
141. Reseland S, Le Noury J, Aldred G, Healy D (2008). National suicide rates 1961-2003: further analysis of Nordic data for suicide, autopsies and ill-defined death rates. *Psychotherapy and Psychosomatics* 77, 78-82
142. Healy D (2008). Our Censored Journals. *Mens Sana Monographs* 6, 244-256, <http://www.msmonographs.org/preprintarticle.asp?id=39302>
143. Healy D (2008). Irrational Healers? *Psychotherapy and Psychosomatics* 77, 198-200. Doi: 10.1159/000126070
144. Healy D, Harris M, Farquhar F, Tschinkel S, LeNoury J (2008). Historical overview: Kraepelin's impact on psychiatry. *Eur Arch Psychiatry Clin Neurosci* 258, suppl 2, 18-24.
145. Le Noury J, Khan A, Harris M, Wong W, Williams D, Tranter R, Healy D (2008). The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts 1875-1924 and 1994-2006 compared. *BMC Psychiatry* 8: 67. doi:10.1186/1471-244X-8-67.
146. Healy D (2009). Trussed in Evidence: Ambiguities at the interface of clinical practice and clinical evidence. *Transcultural Psychiatry* 46, 16-37. 10.1177/1363461509102285.
147. Healy D, Brent D (2009). Are Selective Serotonin Reuptake Inhibitors a risk factor for adolescent suicides? *Canadian Journal of Psychiatry* 54, 69-71.

148. Healy D (2009). Perplexity is our product. *Canadian Journal of Psychiatry* 54, 76.
149. Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson I (2009). The effect of serotonergic and noradrenergic antidepressants on emotional processing in clinically depressed patients. *Journal of Affective Disorders*
150. Healy D, Morgan R, Chinnaswamy S (2009). Transient global amnesia associated with statin intake. *BMJ Case Reports* doi:10.1136/bcr.06.2008.0033.
151. Healy D, Mangin D (2009). The Once and Future Psychiatry. *Academic Medicine* 84, 418-420.
152. Linden S, Harris M, Healy D (2010). Religion and psychosis. *Psychological Medicine* in press.
153. Davies P, Healy D, Green P. Selenium and stereotypes in a mental health setting. *BMJ Case Reports* 2009. in press.
154. Healy D, Mangin D, Mintzes B. The ethics of randomized placebo controlled trials of antidepressants with pregnant women. *Internat J of Risk and Safety in Medicine*
155. Healy D. Science ex Machina. *BMJ* subm.
156. Johnston S, Boehm S, Healy D, Goebel R, Linden DE (2010). Neurofeedback: a promising tool for the self-regulation of emotion networks. *Neuroimage* 49, 1066-1072.
157. Linden SC, Jackson MC, Subramanian L, Wolf C, Green P, Healy D, Linden DEJ. Dissociation between working memory performance and emotion processing in schizophrenia.
158. Mujihad A, Harris, Chellapa P, Lynch K, Healy D. In patient service utilization for paediatric and adolescent mental health disorders

BOOK CHAPTERS

1. Healy D, Carney PA & Leonard B E (1985). Circadian abnormalities in platelet 5HT reuptake in depression. In *Circadian Rhythms in the Central Nervous System*, ed Redfern PH et al. Macmillan Press, Basingstoke, 249-252 (CPA).
2. Healy D (1988). Olfactory Bulbectomy and Depression. In *Animal Models of Psychiatric Disorders* ed Soubrie P et al, 1, 110-114, Karger, Basel (PA).
3. Healy D and Paykel ES (1989). The Neurochemistry of Depression. In *Modern Perspectives in the Psychiatry of the Affective Disorders*, ed Howells, J G, Brunner/Mazel, New York. pps 20-50 (PA).
4. Healy, D (1990). Rhythm and Blues. In *Antidepressants: Thirty Years On*, ed Leonard B E, Spencer P CNS Neuroscience Publishers, London, 169-175 (PA).
5. Healy D (1991). The Role of Irish Members in the Medico- Psychological Association. Plus ca Change. In *150 Years of British Psychiatry* ed Berrios G E, Freeman H L, Gaskell, pp 314- 320 (PA).
6. Healy D, Paykel E S (1992). Neurochemical Correlates of Affective Processes. In *Asbury A K, McKhann G M & McDonald W I, Diseases of the Nervous System*, Harcourt Brace and Jovanovich, PP 815-830 (PA).
7. Lynch T & Healy D (1993). In Conversation with Tom Lynch. In *Talking About Psychiatry*, ed Wilkinson G, Gaskell Press, London (CPA).
8. Healy D (1993). Dysphoria. In *Symptoms of Depression*. ed Costello G Wiley J., pp 24-45 (PA).
9. Healy D (1993). Neuropsychology, pharmacopsychology and schizophrenia. in *Schizophrenia: Aspects and Controversies* ed Bogte H, Verhoeven W M A, Foundation of Neuropsychiatry, Maastricht, pp 30 – 40 (PA).
10. Healy D (1995). Involving users in mental health services in the era of the word-processor and the database. in *Community Care: Evaluation of the Provision of Mental Health Services* ed Crosby C, Barry M, Avebury Press, Aldershot, 209-231.
11. Healy D, Watson F (1995). Human volunteers in human psychopharmacology: Problems and opportunities. in Hindmarch I, Stonier P eds. *Human Psychopharmacology: Materials and Methods*, Vol 5, J Wiley, Chichester, pp 63-87 (CPA).
12. Healy D (1996). Psychopharmacology in the new medical state. in Eds Healy D, Doogan D *Psychotropic Drug Development: Social Economic and Political Issues*, Chapman and Hall, London, pp 15-39 (PA).

13. Healy D, Doogan D (1996). Psychopharmacology in a time of transition. in Eds Healy D, Doogan D, Psychotropic Drug Development: Social Economic and Political Issues, Chapman and Hall, London (PA).
14. Healy D (1996). Irish Psychiatry in the Twentieth Century: Notes Towards a History. in 150 Years of British Psychiatry, Vol 2 ed Freeman H & Berrios GE, Athlone Press, London, 268-291 (PA).
15. Healy D (1996). The history of British Psychopharmacology. in 150 Years of British Psychiatry, Vol 2 ed Freeman H, Berrios GE, Athlone Press, London, p 61-88 (PA).
16. Bentall R, Day J, Rogers A, Healy D, Stevenson R C (1996). Side effects of Neuroleptic Medication: Assessment and impact on outcome of psychotic disorders. in Hdbk of Mental Health Economics and Health Policy, Vol 1 Schizophrenia Ed Moscarelli M, Rupp A & Sartorius N, J Wiley & Sons Chichester, p 133-148 (CPA).
17. Healy D (1998). Drugs & Industry. In Ban TA, Healy D, Shorter E (eds). The Rise of Psychopharmacology & The Story of the CINP, Animula, Budapest. p 51-55 (PA).
18. Healy D (1999). The Origin of the Antidepressants. In Freeman HF (Ed), A Century of Psychiatry, Volume 1, Mosby London, pp 169-173 (PA).
19. Healy D (1999). Arvid Carlsson. In Freeman HF (Ed), A Century of Psychiatry, Volume 1, Mosby, London pp 180-181 (PA).
20. Healy D (1999). Psychopharmacology 2000. In Freeman HF (ed), A Century of Psychiatry, Volume 2, Mosby London, 352-358 (PA).
21. Healy D, McMonagle T (1998). The Prophylaxis of Affective Episodes, O'Mahoney G, Lucey JV, Understanding Psychiatric Treatment, J Wiley & Sons, pp 115-131.
22. Healy D (2000). The Antidepressant Story. In Nowotny H, Folkers G, Sternwarten-Buch Vol 2, Haffmans Sachbuch Verlag Zurich, pp (PA)
23. Healy D (2001). The Antidepressant Drama. In Weissman M ed. Treatment of Depression. Bridging the 21st Century. Proc Am Psychopathological Assoc Meeting March 1999, APA Press, Washington D.C pp 7-34 (PA).
24. Healy D (2001). The SSRI Suicides. In Newnes C, Holmes G, Dunn C (ed), This is Madness Too. PCSS Books, Ross-on-Wye, pp 59-69.

25. Healy D (2001). Fifty Years of Depression. In Dawson A, Tylee A (eds.) Depression: social and economic timebomb. BMJ Books, London, pp.45-48.
26. Randall F, Wood P, Day J, Bentall R, Rogers A, Healy D (2001). Enhancing appropriate adherence with neuroleptic medication: Two contrasting approaches. In Morrison AP (ed). A Casebook of Cognitive Therapy for Psychosis. Brunner-Routledge, London, 281-298.
27. Healy D (2002). Antipsychotics: The Historical Record. In Green B (ed). Focus on Antipsychotics, Petroc Press, Berkshire, pp 4-9.
28. Healy D (2002). Depression. In The New Dictionary of Pastoral Studies, ed Carr W, et al, SPCK Press, London, pp 92-94.
29. Healy D, Kuhn R, Simon P, Broadhurst A, Shorter E, Battegay R, Voelkel A, Cahn CH (2002). The Imipramine Dossier. In Ban T, Healy D, Shorter E (ed), From Neuropsychopharmacology to Psychopharmacology in the 1980s. Animula, Budapest, pp 281-352.
30. Healy D (2004). Psychopharmacology at the Interface between the market and the New Biology. In Rose SPR, Bateson P, Perils and Progress, Cambridge University Press, Cambridge, pp 232-248.
31. Healy D (2005). Psychopharmacological histories through the looking glass of advancing years. In Curran S, Bullock R (eds), Psychopharmacology for the Aged, Practical Aspects, Ratcliffe Medical Press.
32. Healy D (2004). You Have No Right to Present this Research. In Bruneau W, Turk JL (ed.) Disciplining Dissent. Lorimer Toronto, pp 53-73.
33. Healy D (2004). The Foundation of the British Association of Psychopharmacology. In Ban T, Healy D, Shorter E, Psychopharmacology Retrospective, Animula, Budapest.
34. Healy D (2004). Good Science or Good Business. In Chambers T, Elliott C (eds). Prozac as a Way of Life. University of North Carolina Press, Chapel Hill S Carolina, 72-79.
35. Healy D (2005). The Medico-legal interface between Law and Science: From Thalidomide to Prozac. In Tomossy G, et al.
36. Healy D (2004). Drug Regulation and the introduction of psychotropic drugs in the United Kingdom. In Ban T, Healy D, Shorter E. Reflections on Twentieth Century Psychopharmacology. Animula, Budapest, pp 94-97.

37. Healy D (2004). Michael Shepherd, Founder and Vice-President (1957-1958). In Ban T, Healy D, Shorter E. Reflections on Twentieth Century Psychopharmacology. Animula, Budapest, pp 577-578.
38. Healy D (2004). The History of the British Association for Psychopharmacology. In Ban T, Healy D, Shorter E. Reflections on Twentieth Century Psychopharmacology. Animula, Budapest, pp 628-630.
39. Healy D (2005). Shaping Discontent. The Roles of Science and Marketing. In Pietekainen P (ed). Modernity and Its Discontents: Sceptical Essays on the Psycho-medical Management of Malaise. Stockholm: Ax:son Johnson Foundation, pp 33-48.
40. Healy D (2004). A l'heure des antidépresseurs. In Chapelle G (ed). Le Moi. Du Normal au pathologique. Éditions Sciences Humaines, Auxerre, 319-325.
41. Healy D (2006). The New Medical Oikumene. In Petryna A, Lakoff A, Kleinman A (ed) Global Pharmaceuticals. Ethics, Markets, Practices. Duke University Press, Durham, pp 61-84
42. Healy D (2006). Psychopharmacology and the Quantities of the Brain. In Ban T, Ucha Udabe R, (Ed) The Neurotransmitter Era in Neuropsychopharmacology in a Historical Perspective. Editorial Polemos, Buenos Aires, pp 247-254.
43. Healy D (2007). Folie to Folly, The Modern Mania for Bipolar Disorders and Mood Stabilizers. In Tone A, Watkins ES (ed). Medicating Modern America. Prescription Drugs in History. New York University Press pp 42-62.
44. Healy D, Le Noury J (2007). Bipolar Syndrome by Proxy. The Strange Case of Pediatric Bipolar Disorder. In Olfman S (ed). Bipolar Disorder in Children: Cutting Edge Controversies. Praeger Press, 12-27
45. Healy D (2008). The Intersection of Psychiatry and Psychopharmacology in the Second Half of the Twentieth Century. In Wallace ER, Gach J (eds) History of Psychiatry and Medical Psychology. New York, Springer, pp 419-437.
46. Healy D (2008). Birth, Ritalin, Prozac, Viagra, Death. In Bennett , Carney T, Karpin I (eds). The Brave New World of Health. Federation Press, Sydney p 112-127.
47. Healy D, Moore N (2008). Treatment of Psychiatric Disorders. In Boxtel CJ van, Santoso B, Edwards IR (eds). Drug Benefits and Risks: International Textbook of Clinical Pharmacology. IOS Press, p 675-684.

48. Healy D (2008). Academic Stalking and Brand Fascism. In Turk J, Thompson J Universities at Risk: How Politics, Special Interests and Corporatization Threaten Academic Integrity. Lorimer Press, Toronto p 108-137.
49. Healy D (2009). Notes Towards A Future History of Treatments for Cognitive Failure. In Treating Dementia. Do We Have a Pill for That? Ed. Jess Ballenger, Peter Whitehouse, Constantine Lyketsos, Peter Rabins and Jason Karlawish. Johns Hopkins University Press, Baltimore pp 25-41.
50. Healy D (2009). From Mania to Manic-Depressive Illness to Bipolar Disorder, Yatham L, Maj M (eds) Textbook of Bipolar Disorder, J Wiley & Sons

JOURNAL REVIEWER FOR:

1. Academic Medicine
2. Acta Psychiatrica Scandinavia
3. Annals of Internal Medicine
4. Archives of General Psychiatry
5. Behavioural Pharmacology
6. British Journal of Psychiatry
7. British Journal of Clinical Pharmacology
8. British Journal of Hospital Medicine
9. British Medical Journal
10. Biological Psychiatry
11. Biomedical Central
12. Bipolar Disorders
13. BMJ Case Reports
14. BMJ Evidence Centre
15. Bulletin of History of Medicine
16. Canadian Medical Association Journal
17. Chemical Heritage
18. Chronobiology International
19. Clinical Practice & Epidemiology in Mental Health
20. CNS Drugs
21. Contemporary Psychology
22. Culture, Medicine & Psychiatry
23. Current Medical Research & Opinion
24. Current Anthropology
25. Depression and Anxiety
26. Disease Management & Health Outcomes
27. European Neuropsychopharmacology
28. Expert Review of Neurotherapeutics
29. Harvard Review of Psychiatry
30. Hastings Center Report
31. History of Psychiatry
32. History of Psychology
33. History of the Human Sciences
34. Human Psychopharmacology
35. International Journal of Geriatric Psychiatric
36. International Journal of Clinical Psychopharmacology
37. International Journal of Law and Psychiatry
38. International Journal of Neuropsychopharmacology
39. International Journal of Psychiatry in Clinical Practice
40. Internet Journal of Mental Health
41. Irish Journal of Medical Science

42. Irish Journal of Psychological Medicine
43. Journal of Abnormal Psychology
44. Journal of Affective Disorders
45. Journal of Attention Disorders
46. Journal of Child Psychology and Psychiatry
47. Journal of Clinical Psychiatry
48. Journal of the History of the Behavioral Sciences
49. Journal of Mental Deficiency Research
50. Journal of Nervous & Mental Disease
51. Journal of Mental Health
52. Journal of Personality & Social Psychology
53. Journal of Psychiatry & Neuroscience
54. Journal of Royal Society of Medicine
55. Journal of Sex and Marital Therapy
56. Journal of Social and Clinical Psychology
57. Journal of Psychopharmacology
58. Lancet
59. Life Sciences
60. Medical History
61. Medical Hypotheses
62. Mens Sana Monographs
63. Monash Bioethics Review
64. Nature Medicine
65. Nature Neuroscience
66. Neuropsychiatric Disease & Treatment
67. Neuropsychopharmacology
68. Perspectives in Biology & Medicine.
69. Pharmacology, Biochemistry & Behaviour
70. Philosophy, Psychology & Psychiatry
71. Philosophy, Ethics and Humanities in Medicine
72. PLoS Medicine
73. PLoS One
74. Primary Care Psychiatry
75. Progress in Neuropharmacology & Biological Psychiatry
76. Psychiatric Bulletin
77. Psychiatry Research
78. Psychological Medicine
79. Psychology & Psychotherapy
80. Psychopharmacology
81. Psychosis

- 82. Psychotherapy & Psychosomatics
- 83. Public Library of Science: Medicine
- 84. Quarterly Journal of Mental Health
- 85. R&D Management
- 86. Social History of Medicine
- 87. Social Science and Medicine
- 88. Social Studies of Science
- 89. The Psychologist
- 90. Transcultural Psychiatry
- 91. World Psychiatry

ASSESSOR FOR:

Agence d'évaluation des technologies et des modes d'intervention
en santé de Québec.

American Psychological Association Guidelines on the Treatment of Children and
Adolescents.

Drugs and Therapeutics Bulletin
Health Which?
Medicine's Resource Centre Bulletin
Welsh Health Gains Initiative

UNIVERSITY PRESS & PUBLISHER REVIEWS

1. Anansi Press
2. Basic Books
3. Bloomsbury USA
4. Cambridge University Press
5. Chapman & Hall
6. Columbia University Press
7. Duke University Press
8. Encyclopedia of Social Measurement – Elsevier
9. Harvard University Press
10. Hodder & Arnold
11. Johns Hopkins University Press
12. Martin Dunitz Press.
13. New York University Press
14. Oxford University Press
15. Pantheon Books
16. Praeger Publishers
17. Routledge
18. Simon & Shuster
19. Times Literary Supplement
20. University of California Press.

EDITORIAL BOARD

Human Psychopharmacology	1990 – 2000
Primary Care & Community Psychiatry	1995 –
History of Psychiatry	2002 –
Medical Hypotheses	2003 –
Mens Sana Monographs	2007 –
Psychosis	2007 –

GRANT REVIEWER

1. ESRC
2. Canadian Institutes of Health Research
3. MacArthur Fellowship Reviewer
4. Medical Research Council of Canada
5. Medical & Social Science Research Board
6. Mental Health Foundation
7. National Institute for Health Research
8. National Lotteries Charities Board
9. National Science Foundation
10. Scottish Health Board
11. Social Sciences & Humanities Research Council of Canada
12. Wellcome Trust
13. Welsh NHS Research and Development Board

Academic Promotion Review

1. Renselaar Polytechnic Institute
2. Trent University
3. University of California, Los Angeles

GOVERNMENT CONSULTANT

Medical and HealthCare Devices Regulatory Agency (UK) 2001-2004 on SSRIs

Senator Grassley's Office US re SSRIs

Congressmen Barton and Greenwood US re SSRIs

House of Commons Health Select Committee on the Influence of the Pharmaceutical Industry.

Comité d'évaluation des pratiques médicales en matière de médicaments (Belgium)

ABSTRACTS, REVIEWS, CONSENSUS STATEMENTS, LETTERS

1. Healy D, Carney A P, Leonard B E (1984). Abnormalities in the Circadian Regulation of 5HT Uptake into the Platelets of Depressed Persons. *Clinical Neuropsychopharmacology*.
2. Healy D, Carney A P, O'Halloran A (1984). Use of a Microcomputer to rate Depression in a West of Ireland Population. *Clinical Neuropsychopharmacology*.
3. Healy D, Paykel E S, Theodorou A E, Horton R (1988). The effect of treatment with and withdrawal from antidepressants on platelet 3H Imipramine binding in volunteers. *Journal of Psychopharmacology*, 2, 2
4. Healy, D (1988). Antidepressants and Mania. *American Journal of Psychiatry*, 145, 706-707.
5. Healy D (1988). Rhythm & Blues: the role of the circadian rhythm disturbances in the pathogenesis of the affective disorders. *J Psychopharmacology*, 2, 3 abstract.
6. Healy D (1987). Depression & Mania; Modern Lithium Treatment. *Journal of Psychopharmacology* 1, 274-275.
7. Healy D, Paykel ES, Whitehouse AM, White W, Brown M, Ashby M, Theodorou AE, Horton RW (1989). Plasma noradrenaline, adrenaline and DHPG levels in depression before and after clonidine. *J Psychopharmacology* 3, 4.
8. Healy D (1990). Prescribing rights for psychologists? *The Psychologist* 556-557.
9. Healy D (1991). Biological bases of dementia. *Journal of Psychopharmacology* 5, 437-444.
10. Creaney W, Murray I, Healy D (1992). Antidepressant induced suicidal ideation. *Journal of Psychopharmacology* 6, Abstracts of Annual BAP Meeting, 120.
11. Healy D, Calvert J, White W, Whitehouse AM, Paykel E S (1992) Acid Alpha-1 Glycoprotein levels in Depression. *Journal of Psychopharmacology* 6, Abstracts of Annual Meeting 1991.
12. Healy D (1991). Altered States of Consciousness: Phenomenology and Pharmacology. *Journal of Psychopharmacology Abstracts of Annual Meeting*.
13. Healy D (1992). Pandora's Box. *Journal of Psychopharmacology* 6, 444-446.

14. Healy D (1991). The Anxiolytic Jungle. Where Next? *Psychological Medicine* 21, 791-812.
15. Healy D (1991). Medical Choices; Medical Chances. *Irish Journal of Psychological Medicine* 8, 189
16. Healy D, Creaney W (1991). Antidepressant induced suicidal ideation. *British Medical Journal* 303, 1058-1059.
17. Healy D, Waterhouse (1992). Endogenous Rhythms, Reactive Clocks and Non-Specific Drugs. *Journal of Psychopharmacology* A29, abstract 113
18. Healy D (1993). The psychological treatment of insomnia. *Irish Journal of Psychological Medicine* 10, 62.
19. Healy D (1990). A new science of insanity. *New Scientist* 128, 34-38.
20. Healy D (1990). Prescribing rights for psychologists? *Psychologist* 3, 556-557.
21. Healy D (1991). The Hamilton Scales. *British Journal of Psychiatry* 158, 877.
22. Healy D (1991). Sounds from the Bell Jar. *British Journal of Psychiatry* 159, 755-756.
23. Todrick A (1991). Imipramine and 5HT reuptake inhibition. *Journal of Psychopharmacology* 5, 263-267. (ed D Healy).
24. Healy D (1991). Symposia summaries. *J Psychopharmacology* 1, 437-438.
25. Healy D (1992). The Diagnosis of Depression. *Human Psychopharmacology* 7, 154.
26. Lynch T & Healy D (1992). In Conversation with Tom Lynch *Psychiatric Bulletin* 16, 65-72.
27. Healy D (1992). Psychopharmacology for the psychotherapist. *Human Psychopharmacology* 7, 68.
28. Healy D (1992). The Scientific Basis of Psychiatry. *British Journal of Hospital Medicine*.
29. Healy D (1992). The indemnification of psychopharmacology. *BAP Newsletter* Autumn 1992.

30. Healy D, Waterhouse A M (1992). Reactive rhythms, endogenous clocks and non-specific drugs. *Journal of Psychopharmacology, Abstracts of Annual Meeting Summer 1992*, A 29.
31. Healy D (1993). Grangegorman. *Irish Journal of Psychological Medicine* 10, 130-131.
32. Lader M, Healy D et al (1992). The Medical Management of Insomnia in General Practice. *Royal Society of Medicine, Round Table Series no 28*.
33. Healy D (1993). Grangegorman. *History of Psychiatry* 4, 297-298.
34. Healy D (1992). The Beta-Adrenergic Receptors. *Human Psychopharmacology* 7, 357.
35. Healy D (1993). The Aspirin Wars. *BAP Newsletter Spring 1993*.
36. Healy D (1993). Matching the Drug to the Patient's Needs. The prescription of hypnotics. *Prescriber* 4, 12, 36-45.
37. Healy D (1993). Oedipus at Delphi. *British Journal of Psychiatry* 163, 119 - 121.
38. Healy D (1993). Human Psychopharmacology: Materials and Methods Volume 4. *Human Psychopharmacology* 8, 223.
39. Healy D (1993). Beyond the Receptor: the role of Molecular Biology in Psychopharmacology. *Journal of Psychopharmacology* 8, 69-70.
40. Healy D (1994). Human Psychopharmacology: Materials and Methods Volume 4. *British Journal of Psychiatry* 164, 428-429.
41. Healy D. (1993) 'Make Believes' in Psychiatry or the Perils of Progress. *Human Psychopharmacology* 8, 448.
42. Healy D (1993). Brain Dead, Brain Absent, Brain Donor. *Irish Journal of Psychological Medicine* 10, 170-171.
43. Healy D (1993). The psychological treatment of insomnia. *Irish J of Psychological Medicine* 10, 62.
44. Healy D (1994). The Psychological Management of Schizophrenia: Problems and Opportunities. *British Journal of Psychiatry, Royal College of Psychiatrists Annual General Meeting Cork 1994*.

45. Harborne G, Healy D, Watson F L, Groves L (1993). The neuropsychological effects of ketamine: the dog that didn't bark. *Journal of Psychopharmacology, Abstracts of BAP Annual Meeting, 1993, A19.*
46. Pasteur M-A L, Watson F L, Healy D (1993). The cognitive effects of paroxetine in healthy and depressed elderly subjects. *Journal of Psychopharmacology, Abstracts of BAP Annual Meeting, 1993, A18.*
47. Healy D (1994). La Mettrie: Medicine, Philosophy and Enlightenment. *Irish J Psychological Med* 11, 50.
48. Healy D (1994). Chronic Fatigue Syndrome. *J Psychopharmacology* 8, 191.
49. Healy D (1994). Psychobiology & cognitive therapy of the neuroses. *J Psychopharmacology* 8, 279.
50. Healy D (1994). Listening to Prozac (Kramer versus Kramer). *Psychological Medicine* 24, 1048-1050.
51. Wilkinson G, Fahy T, Russell G, Healy D, Marks I, Tantam D, Dimond B (1995). Case reports and confidentiality. *British Journal of Psychiatry* 166, 555-558.
52. Nakielny J, Healy D (1994). The fluoxetine and suicide controversy. *CNS Drugs*, 2, 252-254.
53. Healy D (1994). Beyond the receptor; the significance of gene expression for psychopharmacology. *J Psychopharmacology* 8, 69-70.
54. Healy D (1995). Biology of Depressive Disorders. *Human Psychopharmacology* 10, 68.
55. Healy D (1994). Cocaine. *Drugs of Abuse: A comprehensive series for clinicians. Human Psychopharmacology* 9, 447.
56. Healy D (1995). From fasting saints to anorexic girls. *Irish J Psychological Medicine* 12, 41-42.
57. Healy D. (1995). Cocaine: Physiological and Physiopathological Effects. *Human Psychopharmacology* 10, 163.
58. Healy D (1995). Clinical Evaluation of Psychotropic Drugs. *Human Psychopharmacology* 10, 249.
59. Healy D (1994). Psychobiology and cognitive therapy of the neuroses. *Journal of Psychopharmacology* 8, 279.

60. Healy D (1995). The proscription of prescription. *The Psychologist* April 1995, pp 223 et seq.
61. Healy D (1995). Current insights on obsessive-compulsive disorder. *Human Psychopharmacology* 10, 248.
62. Healy D (1995). Critical Issues in the Treatment of Affective Disorders. *Human Psychopharmacology* 10, 357.
63. Healy D (1995). Bipolar affective disorder. in *Mental Health. A Technical Document produced by the Welsh Health Gain Panel of Review*. Ed Farmer A, p 145-156.
64. Healy D (1995). Clinical Psychopharmacology. *Human Psychopharmacology* 10, 495.
65. Healy D (1995). Clinical Measurement in Drug Evaluation. *Human Psychopharmacology* 10, 494.
66. Watson F, Harborne CG, Tipper ST, Healy D (1995). Ketamine, negative priming and the breakdown of integrative perceptual processes. *J Psychopharmacology* 9, 3, A3, abstract 170.
67. Johnstone F, Rickard I, Healy D (1995). The costs of psychotropic medication. *British Journal of Psychiatry* 167, 112-113.
68. Healy D (1995). Alzheimers and Parkinson's disease. *J Psychopharmacology* 10, 257.
69. Healy D (1996). The NMDA receptor. *J Psychopharmacology* 10, 171.
70. Healy D (1996). Drugs and Addictive Behaviour. *J Psychopharmacology* 10, 257.
71. Healy D (1996). Biological Psychiatry. *Human Psychopharmacology* 11, 429.
72. Healy D (1996). Handbook for the Treatment of the Seriously Mentally Ill. *Human Psychopharmacology* 11, 527.
73. Guest JF, Hart WM, Cookson RF, Lindstrom E (1996). Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. *British Journal of Medical Economics* 10, 59-67. Based on Delphi panel contributions for DH and others.
74. Healy D (1997). In Brodie's shadow. *J Psychopharmacology* 11.

75. Healy D (1997). Narrative, history and accuracy. *J Psychopharmacology* 11, 95.
76. Healy D (1997). Blues in the Night. *The Nursing Times*. April 9th.
77. Healy D (1997). Clinical Handbook of Psychotropic Drugs. *J Psychopharmacology* 11, 96.
78. Healy D (1997). Reply to AJ Goudie – what is the clinical significance of the discontinuation syndrome seen with clozapine? *J Psychopharmacology* 14, 191.
79. Healy D (1997). Architects of the Great Depression. *Times Higher Education Supplement* June 18th
80. Healy D (1997). Child and adolescent clinical psychopharmacology. *Human Psychopharmacology* 12, 168.
81. Healy D (1997). Pleasure and Quality of Life. *Human Psychopharmacology* 12, 168.
82. Healy D (1997). History of Psychiatry. *Human Psychopharmacology* 12, 398.
83. Healy D (1998). Deconstructing Psychopathology. *Psychological Medicine* 28, 744-745.
84. Healy D (1998). The Invention of Depression. *Openmind*
85. Healy D, Farquhar G, Watson F, Tipper S (1998). Varieties of hallucinatory experience and their neural basis. *J Psychopharmacology* 12, A2, abstract 5.
86. Tansey EM, Christie DA, Reynolds LA (1998). Wellcome Witnesses to Twentieth Century Medicine. Vol2. *Drugs in Psychiatric Practice*. Pp 133-205. I have a number of contributions in this.
87. Mortimer A, Healy D, Gray R, Peveler R, Pratt P, Sharma T, Turner T (1998). Consensus statement on schizophrenia standards in care for maintenance therapy and poorly responding/treatment intolerant patients. CINP meeting Glasgow July, *Int J Neuropsychopharmacology*.
88. Healy D, Savage M, Thomas P (1998). Abusive Prescribing. *Openmind* September.
89. Healy D (1998). Conquering Schizophrenia. *Human Psychopharmacology* 13.
90. Hirschfeld RM, Keller M, Bourgeois M, Baldwin DS, Healy D, Humble M, Kasper S, Montgomery S (1998). Focus on social functioning in depression. *Int J of Psychiatry in Clinical Practice* 2, 241-243.

91. Healy D (1998). The Management of Depression. *Int J Psychiatry in Clinical Practice* 2, 313.
92. Healy D (1999). Staying Sane. *Psychological Medicine* 29, 496-498.
93. Healy D (1998). From Placebo to Panacea: Putting Psychiatric Drugs to the Test. *Human Psychopharmacology* 13, 591.
94. Healy D (subm). Noradrenaline, serotonin and social functioning: an overview of implications for the patient. *Psychiatric Services*.
95. Healy D (1999). Differential effects of reboxetine and fluoxetine on social functioning: implications for treatment. In *Depression and Social Functioning: the role of reboxetine, a new selective noradrenaline reuptake inhibitor*. Pennine Press, Macclesfield, pp 49-54.
96. Healy D (1999). The clinical and theoretical significance of differences between reboxetine and fluoxetine on measures of social functioning. In *Improving Social Functioning Through Effective Antidepressant Therapy: the role of reboxetine, a selective noradrenaline reuptake inhibitor*. Pennine Press.
97. Healy D (1999). The Discovery of the Antidepressants. In *Depression and Social Functioning: the role of reboxetine, a new selective noradrenaline reuptake inhibitor*. Pennine Press, Macclesfield pp 4-10.
98. Boardman A, Healy D (1999). Suicide rates in primary care affective disorders. *J Psychopharmacology* 13, abstract P140.
99. Healy D (1999). Trouble in the Freudian Gulf. *British Medical Journal* 318, 949.
100. Healy D (1999). On the History of Lunacy. *British Medical Journal* 319, 63.
101. Healy D (1999). History of the Treatment of the Schizophrenias. *Current Opinion in Psychiatry* 12, S-135-3, p 281.
102. Healy D (1999). Prescriptions, licences and evidence: a reply. *Psychiatric Bulletin* 23, 442-443.
103. Hirschfeld RM, Montgomery SA, Keller M, Kasper S, Schatzberg A, Moller HJ, Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois ML (2000). Social functioning in depression. *J Clinical Psychiatry* 61, 268-275.
104. Healy D (1999). Loss of anxiety and increased aggression in a 15 year old boy taking fluoxetine. *Psychopharmacology* 13, 421.

105. Healy D (2000). The Evolution of Hypnotism. *British Medical Journal* 320, 1015.
106. Healy D (2000). Sitting on it. Feature on Drug-induced akathisia. *Openmind*, March p 18.
107. Healy D, Langmaak C, Savage M (2000). Suicidio en el curso del tratamiento antidepressivo. *Revista de Toxicomanias* 25, 4, 31-40.
108. Healy D (2000). Medicating Schizophrenia. *Journal of Nervous and Mental Disease* 188, 717-719.
109. Healy H, Cattell D, Tranter R, Jaffar K, Healy D (2000). Better than Well on antidepressants. *J Psychopharmacology* 14, 3, abstract PC22.
110. Healy D (2000). Antidepressant associated suicidality. *J Psychopharmacology* 14, 3, abstract PC23.
111. Healy D (2001). From neuroplegics, through neuroleptics to antipsychotics. *World J Biological Psychiatry* 2, 15, 167S.
112. Healy D (2001). When Interests Conflict. *Pharmaceutical Executive*, August p 98.
113. Healy D (2001). Have drug companies hyped social anxiety disorders to increase sales? Yes. Marketing hinders the discovery of long-term solutions; Response from David Sheehan. *Western Journal Medicine* 175, 364-365.
114. Berrios GE, Healy D (2002). How Tainted has Medicine Become? *Lancet* 359, 1775-1776.
115. Healy D (2002). SSRIs and deliberate self-harm. *British Journal of Psychiatry* 180, 547-548, with replies from Pfizer and Glaxo SmithKline.
116. Healy D (2002). SSRI withdrawal: how to avoid problems. *The Prescriber* 13, 91-92.
117. Serlin D, Healy D (2002). Me, Myself and SuperMe. An interview with David Healy. *Cabinet*, Fall issue, pp 75-78.
118. Healy D (2002). Mad in America. *Mental Health Today*, December p 40.
119. Healy D (2003). Pharmaceutical Ethics. *Mental Health Today* Feb, p 34.

120. Shepherd M, Healy D (2003). Psychopharmacology: Specific and Non-Specific. In *Epidemiologia e Psichiatria Sociale* 12, 22-43.
121. Translation from Delay JM, Deniker P, Harl JM. (1952/2003). The psychiatric use of a selective centrally acting phenothiazine (RP 4560). *Annales Medico-Psychologiques*.
122. Translation from Deniker P, Sempe J-C (1967/2003). Psychopathic Personalities. An attempt at a structural definition. *L'Encephale* 56, 5-32.
123. Translation from Deniker P (1969/2003). Hysteria with minimal symptoms. *Confrontations Psychiatriques* 4, 87-98.
124. Translation from Deniker P (1975/2003). Who invented the Neuroleptics? *Confrontations Psychiatriques* 13.
125. Translation from Deniker P, Ginestet D (1975/2003). The psychological effects of the neuroleptics. *Confrontations Psychiatriques* 13,
126. Translation from Deniker P, Colonna L, Loo H, Petit M (1979/2003). Pharmacopsychoses and the 'Deficit' syndrome. *L'Evolution Psychiatrique* .
127. Healy D (2003). Agensi zivotnog stila. *Vreme*, March 28th, pp 36-40.
128. Healy D (2003). A l'heure des antidepresses. *Sciences Humaines* 138, May, 28-31.
129. Healy D (2003). The Hour of our Death. *British Medical Journal* 327, 230.
130. Healy D (2003). Madness Explained. *The Independent Magazine*, Saturday 10th August page 22.
131. Healy D (2003). Inside the Company Mind. *OpenMIND*.
132. Healy D, Harris M, Chandran S, Chakraborty N (2003). Mood-Stabilisers: Impact on Clinical Practice. *Journal of Psychopharmacology* 17, A 46
133. Healy D (2002). Are concerns about the ethics of placebos a stalking horse for other issues? *American Journal of Bioethics* 2, 17-19. Commentary on Miller F, Brody H, What makes placebo-controlled trials unethical? (PA- R)
134. Healy D, Harris M, Tranter R, Austin R, Gutting P, Jones-Edwards G, Roberts AP (2003). Suicide in the Course of the Treatment of Schizophrenia. *Journal of Psychopharmacology* 17, E47.

135. Do SSRIs increase the risk of suicide? Correspondence from Drs Rihmer and Benazzi, with reply. *Psychotherapy and Psychosomatics* 2003, 72, 357-360.
136. Do SSRIs increase the risk of suicide? Correspondence with Drs P Casey, Painuly and Basu with replies from DH. *Psychotherapy and Psychosomatics* 2004, 73, 260-264
137. Healy D (2003). Conspiracy of Consensus. *Mental Health Today*, Nov, 27-31.
138. Healy D (2004). The impact of psychopharmacology on psychiatry and society. *European Psychiatry* 19 suppl 1, Abstract 48.05, page 28.
139. Healy D, Aldred G (2004). Death, Dependence and Deception. *Journal of Psychopharmacology* 18, 285-287.
140. Healy D (2004). In the Balance. Treating Young People with Psychotropic Medication. *Young Minds* 70, 20-21.
141. Healy D (2004). The impact of psychopharmacology on psychiatry and society. *European Psychiatry* 19, suppl 1, page 28, Abstract S48.05.
142. Herxheimer A et al (2004). Open letter to Annette King, Minister of Health, New Zealand. *British Medical Journal* 329, 51.
143. Healy D (2004). Prozac. Les bonnes fortunes d'une molécule. L'enfance turbulente de la star des antidépresseurs. *La Recherche hors Série August* 16th 12-19.
144. Healy D (2004). ISRS. Un risque trop vite effacé. La littérature médicale a occulté la risque suicidaire lié aux antidépresseurs ISRS. *La Recherche hors Série August* 16th 24-27.
145. Aldred G, Healy D (2004). Antidepressants and the risk of suicide. *British Medical Journal* 329, 461.
146. Healy D (2004). Hey, this new drug – it's to die for... *The Times Higher Education Supplement*, September 10th, 20-21.
147. Healy D (2004). Transparency and trust. *British Medical Journal* 329, 1345.
148. Healy D (2005). With this Prize, everyone will be a winner. Review of Strong Medicine. *Times Higher Education Supplement* July 8th p 27.

149. Healy D (2005). Essential Evidence Based Medicine. Times Higher Education Supplement.
150. Healy D (2005). Do selective serotonin reuptake inhibitors cause suicide? British Medical Journal 330, 1148.
151. Fergusson D, Doucette S, Healy D, Shapiro S (2005). Do selective serotonin reuptake inhibitors cause suicide? British Medical Journal 330, 1150.
152. Healy D (2005). The First Cut. A review of The Lobotomist. Nature Neuroscience 8, 695.
153. Healy D (2005). In Open Water. A review of The Trouble with The Drug Companies. Monash Review of Bioethics 24, 58-59.
154. Healy D (2005). Concerns about conflict of interest. J Psychopharmacology 19, 314-315.
155. Healy D (2005). Prozac on the Couch. J of Sex & Marital Therapy 31.
156. Healy D (2005). Manufacturing consensus: More important than manufacturing drugs. Neuropsychopharmacologia Hungarica 7, suppl 1, 33-34.
157. Healy D (2005). The Drug Trial. Monash Review Bioethics 24, 4, 50-55.
158. Healy D (2006). Obituary: Roland Kuhn. History of Psychiatry 16
159. Healy D (2006). Poles Apart. New Scientist 15th April, 38-41.
160. Healy D, Ghaemi N (2006). The best hysterias; the newest mania. PLoS Medicine, plosjournals.org/perlserv/?request=readresponse&doi=10.1371/journal.pmed.0030185
161. Healy D (2006). This new pill will fix it ... The Medicalization Debate. Hospital Doctor June 1st, p 23, with response by R Barker.
162. Healy D (2006). Hasty bolt down the aisle or well-considered union. Academic freedom and commercialism. Times Higher Education Supplement August 18th with response by Robert Jackson MP.
163. Translation from Delay J, Deniker P (1952/2006). 38 Cas de psychoses traitées par la cure prolongée et continue de 4560 RP. C.R.Congrès Méd Alién Neurol France 50, 497-502.

164. Translation from Delay J, Deniker P, Ropert R (1955/2006). Etude de 300 dossiers de maladies psychotiques traités par la chlorpromazine en service fermé depuis 1952. *Encéphale* 528-535.
165. Translation from Delay J, Deniker P, Garnier Mlle (1951/2006). Une grande amnésie de guerre. *Ann Méd Psychol* 109, 544-551.
166. Translation of Delay J, Deniker P, Green A (1959/2006). Essai de description et de définition psycho-pathologique des parents de schizophrènes. In *Second International Psychiatric Congress, Symposium on the Family Milieu of Schizophrenics, Zurich, Sept 4th 1957*.
167. Translation from Delay J, Deniker P, Volmat R, Alby J-M (1956/2006). Une demande de changement de sexe: le trans-sexualisme. *Encéphale* 45, 41-80.
168. Translation from Delay J, Deniker P, Lempérière T, Benoit J-C (1954/2006). Histoire d'un travesty: L'étonisme. *Encéphale* 43, 385-398.
169. Translation from Deniker P, Quintart JC (1961/2006). Les signes pseudo-névrotiques dans les formes limites de la schizophrénie. *Encéphale* 50, 307-323.
170. Translation from Delay J, Deniker P, Dalle B (1966/2006). Les syndromes hallucinatoires idiopathiques chroniques de l'adulte. *Encéphale* 55, 79-94.
171. Healy D (2007). Panic Diaries: A Review. *Bulletin for the History of Medicine* 81, 902-904.
172. Healy D (2007). One Flew over the Conflict of Interest Nest. *World Psychiatry* 6, 26-27; Invited response to Fava G, Financial conflicts of interest in psychiatry.
173. Healy D (2007). Media care and patient pressure. *J Psychopharmacology* 21, 668-670.
174. Healy D (2007). The Cult of Pharmacology. *Perspectives in Biology and Medicine* 50, 467-471.
175. Healy D (2007). Annex 1. Antidepressant medication and other treatments for depressive disorders: A CINP Task Force Report. *Int J Neuropsychopharmacology* 10, supp 1, S179-181.
176. Antonuccio D, Healy D (2008). The researcher's credo. *BMJ* 336, 629.

177. Healy D (2008). SSRIs have a specific risk among antidepressants to cause suicidality. *Int J Neuropsychopharmacology* 11, supplement 1, p 4.
178. Healy D (2008). Paediatric bipolar disorder. *Australasian Psychiatry* 16, 295.
179. Healy D (2009). Psychiatry and the pharmaceutical industry. *British Journal of Psychiatry* 194, 85.
180. Healy D, Charlton BG (2009). Electroshock in Zen and the Art of Motorcycle Maintenance – Fictional not factual. *Medical Hypotheses* 72, 485-486.
181. Kraepelin E, Freud S, Healy D (2009). Kraepelin-Fraud syndrome. *Medical Hypotheses* 72, 378-380.
182. Healy D (2009). On Speed. *Journal of Attention*.
183. Healy D (2009). How marketing created the illusion antidepressants work. *Italian J of Psychopathology* 15, 113-114.
184. Healy D (2009). Psychedelics. *Bulletin of the history of Medicine*
185. Healy D (2009). Amphetamine's Missing History. *Chemical Heritage* 27, p 45.
186. Healy D (2009). Dilemmas of Mind and Soul. *Times Higher Education Supplement*, May 28th.
187. Healy D (2009). Not the Last Word. *BMJ* 339.
188. Healy D (2009). Spontaneous Publications and Academic Miscarriages (SPAM), *BMJ* 339: b4293, p 933.
189. Healy D (2009). Happy Pills in America. *Social History of Medicine* doi:10.1093/shm/hkp083
190. Healy D (2009). Psychedelic Psychopharmacotherapy. *Bulletin of the History of Medicine*
191. Healy D (2009). Obsession. *Bulletin of History of Medicine*.
192. Healy D, Herxheimer A, Menkes D. Induction of violence by psychotropic drugs: signal detection. *Internat Soc of Pharmacovigilance 9th Annual meeting*, poster abstract 213 *Drug Safety* 2009;32: 964.

Articles Journals were too Nervous to Take

1. Healy D (2001). Review of Prozac Backlash. Contemporary Psychology.
2. Healy D (2003). Inside the Company Mind. Open Mind
3. Healy D. Antidepressants and the induction of suicide. Psychiatric Bulletin with Commentary (reviewed and scheduled for publication in 2003)
4. Healy D (2004). The Death of Traci Johnston. Young Minds
5. Healy D (2004). Invited commentary on Jick et al 2004. Evidence Based Mental Health.
6. McHenry L (2005). Review of D Healy Let Them Eat Prozac, accepted for publication in New England Journal of Medicine but not published.
7. McHenry L (2007). Review of D Healy Let Them Eat Prozac. Journal of Medical Ethics stopped on legal advice.
8. Healy D (2005). Regulating the Risks and Benefits of SSRIs. British Medical Journal. Accepted after peer review – finally published 18 months later.
9. Healy D (2005). Partners. Times Higher Educational Supplement Letter.
10. Healy D (2007). A Cuckoo's Egg in the Nest of Science. Index on Censorship.
- 11.

Editorial Responsibility for:

Kraepelin E, Freud S (2009). Kraepelin-Fraud syndrome. Medical Hypotheses.

INVITED PRESENTATIONS

1. Functional variations in platelet rich plasma - Irish Blood Club, September 1981
2. A serotonin receptor assay - Irish Blood Club, Sept 1982
3. The role of adrenergic receptors in mental illness - Irish Neurosciences Group, March 1983.
4. Ambiguities in the uptake of 5HT in platelets from both depressed patients and from controls - Irish Neurosciences Group, October 1984.
5. Two Crows sitting on a Fence - Irish Neurosciences Group, March 1985.
6. Platelet & Neuroendocrine studies in Depression - Irish Neurosciences Group, March 1987.
7. Biochemical Markers in Depression - Pontedilegno Workshop on Membrane Mechanisms in Synaptic Transmission, June 1982 (poster).
8. The Uptake of Serotonin in Depression - Royal College of Psychiatrists, July 1983.
9. Is 5HT induced platelet aggregation a useful index to depression? - British Pharmacological Society, September 1983.
10. Serotonergic Markers in Depression - Brain and Behaviour Workshop, Zuoz, January 1984 (poster).
11. Abnormalities in the Circadian Regulation of 5HT Uptake into the Platelets of Depressed Persons - 14th CINP, Florence, June 1984.
12. Use of a Microcomputer to rate Depression in a West of Ireland Population - 14th CINP, Florence, June 1984 (poster).
13. Rhythm and Blues - Invited Speaker to Symposium on Recent Advances in Biological Psychiatry, Queens University, Belfast, September 1985.
14. Normal and Abnormal Variations in Platelet 5HT Uptake from Control and Depressed Populations - Royal College of Psychiatrists, November 1985.
15. One Hundred and One Uses for a Dead Psychiatrist. Invited Speaker at a Symposium on Animal Models of Depression, BAP Summer Meeting, Cambridge 1987.

16. Mourning, Melancholia and Mood-Altering Drugs - Invited Speaker at a BAP Symposium on Current Developments on Psychopharmacology, in Birmingham, Spring 1988.
17. The effect of treatment with and withdrawal from antidepressants on platelet 3H Imipramine binding in volunteers. BAP Cambridge 1988.
18. Rhythm and Blues - Invited Speaker at a BAP Symposium "Thirty Years Since Imipramine" in Galway, September 1988.
19. Plasma noradrenaline (NA), adrenaline (A) and DHPG levels in depression before and after clonidine. Spring Quarterly Meeting of Royal College of Psychiatrists, Galway, 1990.
20. Antidepressant induced suicidal ideation. Free Communications BAP Annual General Meeting, York 1991.
21. Acid Alpha-1 Glycoprotein levels in Depression. Free Communications, BAP Annual General Meeting, York 1991.
22. Altered States of Consciousness: Phenomenology and Pharmacology. BAP Annual General Meeting York 1991, Invited Speaker.
23. Clinical Chickens and Marketing Eggs. BAP Spring Meeting, North Wales 1992, Invited Speaker.
24. Endogenous Rhythms and Reactive Clocks. BAP Annual General Meeting Cambridge 1992, Invited Speaker.
25. Neuropsychology, Pharmacopsychology and Schizophrenia. Second International Symposium on Schizophrenia, Maastricht Nov 1992.
26. The Enigma of Irish Psychiatry. European Association for the History of Psychiatry, Third General Meeting London August 1993.
27. The Role of Drug Treatment in Psychiatric Rehabilitation. Third World Congress for Psychosocial Rehabilitation, Dublin Sept. 1993.
28. The Enigma of Irish Psychiatry. Third World Congress for Psychosocial Rehabilitation, Dublin Sept. 1993.
29. Altered Circadian Rhythms and Depression. European Society for Chronobiology 9th Annual Meeting, Bath, September 1993.
30. The Marketing of Psychotropic Drugs: How the Industry Gets it Right. BAP Winter Meeting, Nov 1993.

31. Healthy Volunteer Research in Psychopharmacology. Milford Symposium IV, Univ of Surrey Guildford January 1994.
32. Psychiatry, Psychotherapy and the Future of Mental Health Services in Primary and Secondary Care. Royal Society of Medicine, Section of General Practice. Jan 1994.
33. Human Psychopharmacological Research with Healthy Volunteers: Problems and Opportunities. BAP Spring Meeting, Birmingham 1994.
34. The Psychological Management of Schizophrenia: Problems and Opportunities. Royal College of Psychiatrists Annual General Meeting Cork 1994.
35. Psychotropic Medication and compliance: a patient-centred approach. Twentieth European Conference on Psychosomatic Medicine, Gent, August 1994.
36. The Industrialisation of Psychiatric Language. Royal College of Psychiatrists. Winter Meeting, Glasgow, 1995.
37. The Role of Abuse in Psychiatric Presentations. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Post Douglas Preconference Symposium, May 1995.
38. The psychotherapy of psychosis. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Cairns, May 1995.
39. The evaluation of psychotherapies. Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Cairns, May 1995.
40. Horizons in addiction therapy. Addiction Section of Royal Australian and New Zealand Colleges of Psychiatry, Annual Meeting, Hamilton Island May 1995.
41. The Discovery of the Antidepressants to the History of Medicine Department, University of Toronto, October 1995.
42. The Influence of Pharmaceutical Developments on Psychiatric Nosology, To the Clarke Institute of Psychiatry - Visiting Lecturer, October 1995.
43. Negative Priming and Psychosis, CINP Melbourne, June 1996.
44. The Invention of Antidepressants, AEP and Royal College of Psychiatrists Meeting London, July 1996.

45. Negative priming in healthy volunteers after neuroleptics, minor tranquillisers and ketamine and in treated and untreated psychotic subjects. ACNP, Dec 1996 (poster).
46. Rhythm & Blues. British Psychological Society, Winter Meeting, London Dec 1996.
47. Innovation in Drug Treatment. NHS Executive (West Midland), Commissioning and Provision of Services for the Severely Mentally Ill. Birmingham March 1997.
48. Wellcome Witness Seminar on The Impact of Psychopharmacology on Psychiatry, March 1997 (serial contributions).
49. The Church, Nationalism and Mental-Illness in Early Twentieth Century Ireland. Wellcome Trust Specialist Seminar on Asylums, Trinity College Dublin June 30th 1997.
50. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. Satellite Symposia at Royal College of Psychiatrists Summer Meeting, Bournemouth 1997
51. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. Satellite Symposia at BAP Annual Meeting Cambridge 1997
52. The Enhancement of Social Functioning as a Therapeutic Principle in the Treatment of Depression. ECNP Annual Meeting Vienna, Sept 1997
53. Methods of Rating Depression in Clinical Trials. 7th Japanese Clinical Neuropharmacology Association meeting. Tokyo, Nov 1997.
54. The Invention of Depression. Scottish Division of Royal College of Psychiatrists, Winter 1998.
55. Does Technology Drive History. Enhancement Technologies Research Group Seminar, University College London, Feb 1998.
56. New Drugs and Old Problems, Mind Conference, London, April 1998.
57. Social Functioning in Depression. Scandinavian Society for Psychopharmacology, Copenhagen, April 1998.
58. Reboxetine, the first selective norepinephrine reuptake inhibitor. American Psychiatric Association Meeting, Toronto, June 1998, New Research Symposium abst NR 228.

59. Physical Treatments in Psychiatry Before 1948. Royal College of Psychiatrists Annual General Meeting, Belfast June 1998.
60. Hallucinations and Psychopharmacology, Invited Symposium Speaker, BAP Annual Meeting, Cambridge July 1998.
61. The History of the Antidepressants, in XX1st CINP Meeting, Glasgow July 1998.
62. The Role of Consensus Statements on Psychotropic Drugs in Therapeutics in Learning Disabilities Conference, Nottingham November 1998.
63. The Antidepressant Project. American Psychopathological Association Meeting, New York, March 1999.
64. The Antidepressant Era, The Annual Raths-Steiger lecture, Zurich, June 1999.
65. Modelling suicide risk in primary care primary affective disorders. British Association of Psychopharmacology Annual Meeting Harrogate July 25th 1999 (poster).
66. History of the Treatment of the Schizophrenias, World Psychiatric Association meeting History of Psychiatry Section Symposium, Hamburg August 1999.
67. The rational basis for prescribing antidepressants. European College of Neuropsychopharmacology London, Sept 1999.
68. Neuroleptic Discontinuation Syndromes. United Kingdom Psychiatric Pharmacists Annual Meeting, November 1999.
69. The expansion of the therapy industry in North Wales: 1896 and 1996 compared. St David's Day Conference – Health and Medicine in Wales.
70. Discovery and Development of the Antidepressants: What the History Books won't tell you. McLean Hospital Psychopharmacology Service, Harvard University Boston, March 24th 2000.
71. Psychopharmacology and the Disease Concept. Oslo Department of Psychiatry Annual Psychiatry Symposium, March 31st 2000.
72. Beyond the Disease Concept. Oslo Department of Psychiatry Annual Psychiatry Symposium, March 31st 2000.
73. Antidepressant Associated Suicidality (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000.

74. Antidepressant Associated Suicidality (poster). The British Association of Psychopharmacology meeting in July 2000
75. Antidepressant Associated Suicidality (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
76. Better than Well on Antidepressants (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000,
77. Better than Well on Antidepressants (poster). The British Association of Psychopharmacology meeting in July 2000
78. Better than Well on Antidepressants (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
79. The Social Adaptation Self-evaluation Scale: Effects of antidepressants (poster). This was presented at The Royal College of Psychiatrists meeting in July 2000.
80. The Social Adaptation Self-evaluation Scale: Effects of antidepressants (poster). The European College of Neuropsychopharmacology in Munich Sept 2000.
81. Let Them Eat Prozac. Centre for Freudian Analysis & Research, London, October 2000.
82. The Interface between Psychopharmacology & Society: 1952-2002. In Looking Back, Looking Ahead. Psychiatry in the 21st Century: Mental Illness & Addiction. 75th Anniversary of the U of Toronto's Dept of Psychiatry, November 2000.
83. Psychopharmacology and the Silence of the Cemetery. Grand Rounds Westchester Division, Cornell University, December 2000.
84. The Creation of Depression. Eric T Carlsson Memorial Grand Rounds, Payne Whitney Division, Cornell University, December 2000.
85. Psychotropic Drugs & The Social Contract. Richardson Research Seminar Institute for the History of Psychiatry, Cornell University, December 2000.
86. Psychopharmacology and The Government of the Self. Centre Nationales de Research, Paris, February 2001.
87. The Rise of Corporate Psychiatry. Departments of Psychiatry and Bioethics, University of Minnesota, April 2001.
88. Treating More Patients than Ever Before. 6th Hannah International Symposium, April 2001, Toronto.

89. Good Science or Good Business, SSRIs & Suicide. Joint Centre for Bioethics, University of Toronto, April 19th 2001.
90. The History of Antidepressant Therapies. Korean Society for Psychiatry, April 27th 2001, Seoul.
91. Making an Antipsychotic. First Greek Society of Psychophysiology Meeting, Thessalonika, June 2001.
92. From Neuroleptics to Antipsychotics. World Federation of Biological Psychiatry. July 2001, Berlin.
93. The Drug Dependence at the Heart of European Social Democracy. Royal College of Psychiatrists & World Psychiatric Association Meeting, July 2001, London.
94. Reshaping Personhood and Identity. At Visions of Life, Molecular Politics and Normalisation, Hinxton Hall, Cambridge, July 17th 2001.
95. Evidence Biased Psychiatry. BRAF meeting, University College London, September 19th 2001.
96. Where Neuroscience and Culture Meet. Robert Mayne Annual Lecture, Trinity College Dublin, September 27th 2001
97. What History Teaches Us. Inaugural Meeting of the Irish Psychiatric Association, Kilkenny, October 28th 2001.
98. Cognitive Effects of Psychotropic Drugs. UK Psychiatric Pharmacists Annual Meeting, Reading October 2001.
99. National Institutes of Health Symposium: New Frontiers of Biomedical Research 1945-1980; Psychopharmacology & Behavior, Bethesda, Maryland, Oct 29th 2001.
100. McLean Hospital Grand Rounds – Treating More Patients than Ever Before, Boston November 1st 2001.
101. Harvard Medical Anthropology Program – Psychopharmacology & The Appearances of Science, November 2nd 2001.
102. Social Science: 4S Conference – Analysing Tanya Luhman’s In Two Minds, Invited Discussant November 2001.
103. Hidden Effects of Antidepressants. Adverse Reactions to Psychotropic Drugs Meeting, London, November 8th.

104. Science and Human Agency: Genes, Drugs and Behaviour. Invited Discussant, Gresham College & The Royal Society, London December 2001.
105. The Appearances of Science – London Medical Sociology Group, January 2002
106. Psychiatry™. The troubled relationship between psychiatry and the pharmaceutical industry. Annual Mind Lecture, Institute of Psychiatry February 2002
107. The Appearances of Science, Bradford University, February 2002.
108. Treating More Patients Than Ever Before, Nottingham, March 2002
109. Science & the Degradation of Psychiatric Care, Invited Plenary Lecture Psychotherapy Section of Royal College of Psychiatrists, Annual Meeting Cambridge April 2002.
110. The Fate of Bipolar Disorders 1900 and 2002 Compared, Yorkshire Section of Royal College of Psychiatrists, April 2002.
111. The New Medical Oikumene. Invited Plenary Lecture, Harvard University Dept of Social Medicine, Workshop on Pharmaceuticals and Globalization. May 2002.
112. The Appearances of Science, University of California, Los Angeles, Dept of Psychiatry, UCLA Medical Classics Lecture, May 2002
113. Evidence Biased Psychiatry, Leading Edge Seminars, Toronto May 2002.
114. Psychopharmacology and the Government of the Self, Public Lecture, Toronto May 2002.
115. Psychopharmacology: What you're not being told. Teesside University Conference – The Fish Ain't Sick, the Water's Dirty, September 2002.
116. Dependence on SSRIs. Addiction Research Forum, Durham, September 2002.
117. This House believes that psychiatry has been compromised by its links with the pharmaceutical industry. Debate in the General and Community Faculty Meeting of the Royal College of Psychiatrists, Newcastle, October 18th
118. The Rise of Corporate Psychiatry, Grand Rounds, Ann Arbor, Michigan, October 23rd 2002.

119. Psychopharmacology and the Government of the Self. History of Psychiatry Group, Harvard University Faculty Club October 21st 2002
120. The Emergence of Corporate Psychiatry Grand Rounds, Cambridge City Hospital. October 29th 2002
121. The Corporate Colonisation of the Campus. Queens University, Kingston Ontario, First Annual Lecture on Academic Freedom. November 1st 2002.
122. The Silencing of Dissent. Canadian Association of University Teachers' Meeting on Disciplining Dissent Ottawa, November 1-3, 2002.
123. Psychopharmacology in Historical Perspective. History of Psychiatry Group, Cambridge University. November 2002.
124. Drugs – Whose Profit & Whose Loss? Café Scientifique and The Royal Society, Leeds, Nov 18th.
125. The not-so-everyday psychopharmacology of everyday nerves. University of Toronto, History of Medicine Conference – the Social Sources of Psychopharmacology, February 25th 2003.
126. Risk Societies and the future of psychopharmacology. Dept of Bioethics, University of Toronto, Feb 26th, 2003.
127. Brownbag Research Seminars: Gripped by a Python: How Pharmaceutical Companies Control the Medical Marketplace, February 27th. York University Toronto
128. That this house believes SSRI treatment causes a significant risk of increased suicidality. Affective Disorders Group, North West, Manchester March 2003.
129. The Creation of Psychopharmacology. Salon International de la Salud, Santiago de Compostella, Spain March 2003.
130. This House believes that Suicide is caused by SSRIs. Irish College of Psychiatrists Dublin March 2003.
131. The Role of New Antipsychotics in Mood Stabilization. Plenary Lecture, General Practice Psychotherapy Association Toronto April 4th 2003.
132. Why do we say Doctoring the Data? Robert TM James Memorial Lecture, General Practice Psychotherapy Association Toronto April 3rd, 2003.

133. Academic Freedom and your Sex Life. Academic Freedom & The Public Interest, Simon Fraser University, Vancouver, April 25th.
134. This House Believes that Antidepressants Cause Dependence. Maudsley Hospital/Institute of Psychiatry, Mental Health Care Debate, July 16th, London.
135. Mood Stabilizers: Possible Impact on Service Utilization. British Association for Psychopharmacology – Poster July 2003.
136. Suicide in Schizophrenia. British Association for Psychopharmacology – Poster July 2003.
137. The Construction of the Psychopharmaceutical Marketplace. Plenary Lecture in Vital Politics: Health, Medicine, and Bioeconomics into the 21st Century. London School of Economics Sept 2003.
138. The Psychiatric Dance. Theory and Practice of Mental Health Care During the Twentieth Century. U of Amsterdam – Sept 2003.
139. Psychopharmacology and the Government of the Soul. In Stockholm, Swedish Medical Society, Axel and Margaret Ax:son Johnson Foundation, Seminar: From Hysteria to Depression: Modernity & its Discontents. Sept 25th 2003.
140. Risk Management: the Way of the future in psychopharmacology. In Stockholm, Swedish Medical Society, Axel and Margaret Ax:son Johnson Foundation, Seminar: From Hysteria to Depression: Modernity & its Discontents. Sept 25th 2003.
141. The Construction of the Pharmaceutical Marketplace: Legal Implications. Symposium on Medicine & Industry. 28th International Congress on Law & Mental Health Law, Sydney, Sept 2003.
142. Legal Scientism. 28th International Congress on Law & Mental Health Law, Sydney, Sept 2003.
143. The Interface between Business and Science. Queensland University of Technology, Guest Lecture, October 2003.
144. Emerging trends in Clinical Litigation. Queensland University of Technology, Faculty of Law. Brisbane, October 2003.
145. Depressed, Bothered and Bewildered. Debate on ABC radio with Ian Hickie, Murdoch University Perth, Australia, October 2003.

146. Shaping the Intimate, Guest Lecture, Murdoch University, Perth, October 2003.
147. Academic Freedom in the New Medical State. University of New Brunswick Academic Freedom Lecture, October 2003.
148. Manufacturing patients, Panel Discussion, University of New Brunswick, October 2003.
149. Psychopharmacology and Freedom. World Mental Health Day, Toronto October 2003.
150. Prozac and Paxil: Fireworks at the medicolegal interface. University of Toronto Faculty of Law Seminar Series, October 2003.
151. The New Language of Marketing. Trent University, Ontario, October 2003.
152. How Pharmaceutical Companies Mould Consciousness. Grand Rounds Neuropsychiatric Institute UCLA, Los Angeles, October 2003.
153. Suicide in the Course of the Treatment of Schizophrenia. Grand Rounds, Harbor-UCLA campus, October 2003.
154. Manufacturing Consensus. Plenary Lecture at Is Psychiatry for Sale, A Mind and Critical Psychiatry Meeting, London, November 17th
155. Ghostwriting in the Scientific Marketplace. The political economy of psychiatric drugs and medical authorship. American Anthropological Association Annual Meeting, Chicago, November 19th 2003
156. Shaping the Intimate, Bartlett Visiting Professorship, University of Rochester, New York, Nov 22nd 2003.
157. Mental Health Service Utilization: 1900 and 2000 Compared. Rochester Psychiatric Institute, Grand Rounds, Nov 22nd 2003
158. SSRIs and Suicidal Behavior. Bartlett Visiting Professorship, Workshop, University of Rochester, New York, Nov 23rd 2003.
159. The Interface between Academia and Industry. British Association of Pharmaceutical Physicians Annual Meeting, Industry Sponsored Research, Tainted or Unfairly Maligned, Commonwealth Institute, London, January 2004
160. The Fault line in the Drugs Approval System; Risk First, Safety Later, Health Coalition Canada forum, Ottawa, January 28th 2004

161. Freud – The Second Coming? What the Antidepressant Story says about Psychoanalysis. Emory University, Atlanta January 2004.
162. The Creation of Depression. Georgia Tech, Atlanta, January 2004.
163. Healy D, Debate: This House Believes that Academic Research in Schizophrenia is in bondage to the pharmaceutical industry. In 12th Schizophrenia Annual Winter Workshop, Davos, February.
164. The role of medication in mental health nursing - the Debate. Royal College of Nursing Annual Meeting, Dublin February 2004.
165. How Pharmaceutical Companies Manufacture Cultures. Clinical Trials Research Group, McGill University.
166. Drug Development in Alzheimer's Dementia. Lessons from the History of Drug Development. Johns Hopkins Baltimore March 2004.
167. The impact of psychopharmacology on psychiatry and society. World Psychiatric Association Meeting, Geneva, April 2004.
168. Suicide in the Course of the Treatment of Schizophrenia. American Association for the Advancement of the History of Medicine, Madison Wisconsin April 2004.
169. Marketing Illness. Let Them Eat Prozac. Health Ethics Quarterly Rounds St Boniface Research Centre, Winnipeg May 2004.
170. A conversation with DH. Winnipeg Regional Health Authority, Health Sciences Centre, May 2004.
171. Let Them Eat Prozac, Suicide and Psychotropic Drugs. Nevada State Psychological Association, Annual Conference, Reno Nevada, May 2004.
172. Manufacturing Consensus: The End of Psychiatry as a Science? Scottish Division of Royal College of Psychiatrists, June 2004
173. Schizophrenia: the dangers of current treatments, the need for new approaches. First Horrobin Annual Prize Lecture, London, June 2004.
174. Manufacturing Consensus. How Companies Get Experts Onside. Conference on Integrity in Science Washington July 12th.
175. Manufacturing Consensus. American Association for the Advancement of Science Washington July 13th.

176. The Creation of Depression. American Psychological Association meeting Honolulu July 2004.
177. Birth, Ritalin, Prozac, Viagra, Death. 4S and EASST meeting Paris August 2004.
178. Manufacturing Consensus. 4S and EASST meeting Paris, August 2004
179. Suicide on Antidepressants. International Society of Pharmacoepidemiology, Bordeaux August 2004.
180. Birth, Ritalin, Prozac, Viagra, Death. In Gender and the Meaning of Mental Health, Ann Arbor, Michigan, October 2004
181. Shaping the Intimate, Culture, Brain and Development Program Hampshire College Amherst, October 2004
182. Psychopharmacology & the Government of the Self. Postgraduate Mental Health Seminar Series, Institute of Social Medicine, Rutgers University October 2004.
183. Manufacturing Consensus, The end of psychiatry as a science? International Center for the Study of Psychiatry and Psychology New York October 2004.
184. The Influence of the Pharmaceutical Industry on Psychiatry. Dept of Psychiatry, Vienna. November 2004.
185. Suicide and SSRIs. Brigham and Women's Dept of Epidemiology Boston January 2005.
186. Madness and Medication. The Third Ronnie Laing Conference, London, March 2005.
187. Birth, Ritalin, Prozac, Viagra, Death. Studium Generale Lecture Groningen April 2005
188. Intimate Psychopharmacology. The Psyences Project, Princeton University April 2005.
189. Manufacturing Consensus. Social Sources of Psychopharmacology, U of Toronto. April 2005
190. Dr Jekyll Takes an SSRI; Antidepressants and Homicide. Social Sources of Psychopharmacology, Toronto April 2005

191. Evidence Based Medicine: how it can be misused. American Psychiatric Association Annual Meeting Atlanta May 2005 Symposium 37A
192. Psychopharmacology and Government of the Self. Grey Nuns Hospital, Edmonton Alberta, May 2005
193. Schizophrenia 1900 and 2000 compared. Third Pierre Flor-Henry Lecture, Edmonton Alberta, May 2005.
194. Notes Toward a History of Mood Stabilizers. Royal College of Psychiatry Annual General Meeting, Edinburgh June 2005
195. Shaping the Intimate. Royal College of Psychiatry Annual General Meeting Edinburgh June 2005.
196. Manufacturing Consensus, Annual Invited Guest Lecture, The Priory Hospitals, London.
197. From Folie Circulaire to Bipolar Disorder, International Association for Law and Mental Health Annual Meeting Paris July 2005.
198. This house believes that evidence based medicine has debased psychiatry. North West Regional Meeting Royal College of Psychiatrists Debate with Clive Adams, Bolton Sept 2005.
199. Cognitive Enhancement: Experience with psychotropics. Sheffield Psychopathology Symposium, Sept 2005.
200. Ethics Roundtable: Hazards and Benefits of Antidepressants. Peter Gaszner, Zoltan Rihmer, Gabor Kovacs, Bela Buda, Jozsef Kovacs: Hungarian Psychopharmacology 8th Annual Meeting. Tihany October 2005.
201. Manufacturing Consensus is more important than Manufacturing Drugs. Hungarian Psychopharmacology 8th Annual Meeting. Tihany October 2005.
202. To Err is Human: To really foul up needs evidence based medicine. New Philosophies for Community Psychiatry: Recovery-Oriented, Evidence-Based, and Beyond. 8th Int Conf on Philosophy, Psychiatry and Psychology, Yale, October 2005
203. Psychopharmacology in Turmoil: a Scientific or Ethical Crisis. PET Seminars, Dept of Public Health, Columbia University New York, October 2005
204. The Root of All Evil: Money, People or Power? Canadian Association of Bioethics, Dalhousie University, October 2005

205. Psychopharmacology in Turmoil: A Scientific or Ethical Crisis. Louisiana State University Dept of Psychology & Philosophy
206. Shaping the Intimate. Chancellor's Distinguished Guest Lecture Louisiana State University, Baton Rouge, October 2005.
207. Birth, Ritalin, Prozac, Viagra and Death. Constructions of Health. U of Sydney Dept of Health Law. November 2005.
208. Antidepressants and Homicide. Medications and Criminal Justice, Institute of Criminology & U of Sydney, Dept of Health Law. November 2005
209. The Medico-Legal consequences of pharmaceutical company involvement in developing new drugs. Adverse Drug Reactions, Litigation and Drug Regulation, Sydney Bar Association, October 2005
210. The consequences of ghostwriting and lack of access to clinical trial data in the medico-legal arena. Expert evidence in Health Law. Faculty of Law University of Sydney, November 2005
211. The psychopharmacology of bipolar disorder. Welsh Psychiatric Society, Llandudno, November 2005.
212. Erasmus Prize Public Debate: Is there a crisis of scientific authority? Simon Schaffer, Steven Shapin, Josee van Eijndhoven, David Healy, Hugh Pennington. De Rode Hoed, Amsterdam November 2005
213. Psychopharmacology in Turmoil: an Ethical or Scientific Crisis. Istituto Superiore de Sanitate, Rome December 16th 2005.
214. Psychopharmacology and Modern Cultures. Australian and New Zealand Society for Psychiatry, Psychology and Law, Sydney April 3rd
215. Birth, Ritalin, Prozac, Viagra, Death, Royal Adelaide Hospital Grand Round April 4th
216. The Latest Mania, Women's & Children's Hospital Grand Round, Adelaide, April 5th
217. Suicide rates and other outcomes in Schizophrenia. Royal Adelaide Hospital psych dept internal CME, April 6th
218. Antidepressants: Suicidality, Homicidality & Efficacy. RANZCP college CME in conjunction with Healthy Skepticism, April 6th - Public Lecture.

219. Suicide rates and other outcomes in Schizophrenia. Flinders Medical Centre Psych Dept CME, April 7th
220. Antidepressants & Homicide. Australian and New Zealand Society for Psychiatry, Psychology and Law, Sydney April 8th
221. Antidepressants & Homicide. New South Wales Defence Lawyers Forum, Sydney April 10th
222. The Latest Mania. First International Conference on Disease Mongering, Plenary Lecture, Newcastle Australia, April 11th
223. Melancholia in the 19th, 20th and 21st centuries: similarities and differences. Copenhagen Dept of Psychiatry Symposium on Melancholia, May 2006
224. The New Anecdotes: Evidence Based Medicine and the Degradation of Clinical Practice and Research. In Searching for Gold Standards – the Construction and Governance of RCTs & EBM in Psychiatry. Institute of Psychiatry, June 2006.
225. Bipolar Disorder: a communal disorder. Philosophy, psychiatry and psychology, Leiden University, Holland June 2006.
226. Mood enhancement? Mood Enhancement Workshop. Maastricht, Holland, June 2006.
227. Trussed in Evidence: Guidelines, Tramlines and Faultlines. Health Action International, 25th anniversary meeting, Amsterdam, October 2006
228. Ist die Wirkung von Antidepressiva klinisch bedeutsam? Pro Hans-Juergen Moeller, and Thomas Schlaepfer, Con D Healy. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Berlin, Nov 2006
229. Cargo Cult Science. In Perspectives on Scientific Practice from Science and Scientific Studies, Lorentz Center, Leiden University November 2006
230. A Pleasing Look of Truth. Public Lecture, Leiden University November 2006.
231. Global Business Masquerading as Science. The Human Laboratory. Tokyo December 2006
232. Antidepressants and Suicide. Tokyo University December 2006.

233. Antidepressants and Suicide in the Elderly. Welsh Geriatric Society, Caernarfon, March 2007.
234. Mental Health Services in North Wales. Welsh Assembly Government Meeting Caernarfon, March 2007.
235. This House believes that the UK MHRN should have access to data from studies carried out on behalf of pharmaceutical companies? Mental Health Research Network, London, April 2007.
236. Enhancing and stimulating. Second Mood Enhancement Workshop Maastricht April 28th
237. Kraepelin's impact on psychiatry. Letten Foundation Meeting Emil Kraepelin's Dichotomy. Ludwig Maximilians Universitat, Munich April 30th
238. Trussed in Evidence. UCLA, May 2007.
239. Disease Mongering. American Psychiatric Association Meeting May 2007.
240. The Use of Antidepressants for Anxiety Disorders. Consensus conference on the use of antidepressants for anxiety disorders. Comité d'évaluation des pratiques médicales en matière de médicaments. Brussels May 2007
241. Bipolar Syndrome by Proxy. Pointpark University Pittsburgh June 2007.
242. Cargo Cult Science. McGill Advanced Study Institute, Globalisation and Pharmaceuticals June 2007
243. Brand New Psychiatry. University of Western Ontario, London June 2007
244. Recovery in Psychosis. Royal College of Psychiatrists Annual Meeting Edinburgh 2007.
245. Homicide and Antidepressants. International Association for Law and Mental Health, Padua June.
246. Trussed in Evidence: Ambiguities at the interface between evidence and clinical practice. International Association for Law and Mental Health, Padua June.
247. Tracing pharmaceuticals in South Asia: Regulation, Distribution and Consumption. The Centre for International Public Health Policy. Edinburgh July 2007

248. Academic Stalking. American Psychological Association Annual Meeting San Francisco August 2007.
249. Brand Fascism. Demedicalising misery. University of East London. September 14th.
250. Growing up in a Mad World. Wellcome Collection Public Forum, London September 27th.
251. Academic Stalking. Canadian Association for University Teachers, Annual Meeting, Ottawa, November 2007.
252. Guerilla guide to mental health systems. Ethics and Mental Health, public lecture, Manchester Metropolitan University.
253. Business as usual. The triumph of pharmacology in mental health care. U of Helsinki, Dept of Sociology November 2007.
254. The Human Laboratory. Patients and the Medico-pharmaceutical complex. Mielenterveysmessut, Helsinki, November 2007
255. Swallowing it whole: this house believes that psychiatrists are unable to resist the seductive messages of the pharmaceutical industry. Institute of Psychiatry, November 2007
256. The Human Laboratory. Public Lecture, University of California, San Diego, December 2007
257. So What's the problem with Ghostwriting? European Medical Writers Association and Institute of Clinical Research, Annual Meeting – Publishing Clinical Trials: Ethics and the Pharmaceutical Industry, February 2008
258. Brand Fascism. European Molecular Biology Lab, Heidelberg April
259. Lowering Suicide Rates: Realistic or Quixotic? Association of European Psychiatrists, Nice 2008
260. Does anything stabilize moods? Royal College of Psychiatrists Annual Meeting London June 2008/
261. Antidepressants and Suicide. CINP Meeting Munich July 2008
262. Trussed in Evidence. European Molecular Biology Summer Workshop, Heidelberg, August 2008

263. Selling out or Win-win: the benefit of industry involvement on training of healthcare providers outweighs the harm? International Association of Medical Science Educators, Salt Lake City, July 2008.
264. Trussed in Evidence. European Molecular Biology Laboratories, Summer Workshop, Heidelberg, August 2008.
265. Can psychiatry play a part in reducing suicide rates? Celtic Conference Royal College of Psychiatrists, Edinburgh September 2008
266. Mania. American College of Neuropsychopharmacology Annual Meeting, Plenary Lecture, Phoenix 2008
267. How marketing created the illusion that antidepressants work. 13th National Congress of the Italian Society for Psychopathology (SOPSI) – Rome Feb 13th 2009.
268. The Future of Medical Care. Pitzer College, South California, February 2009.
269. From Jekyll and Hyde to Forensic Psychopharmacology. Patton State Hospital. February 2009.
270. The Future of Medical Care. Society and Genetics, UCLA February 2009.
271. Can Obama's Healthcare Plan Work? UCLA, March 2009.
272. Hypnotizing clinicians: the role of statistical significance testing. UCLA/NPI workshop-seminar March 2009
273. Whither Medicine? Eric Nordlander Lecture, Cornell University, New York March 2009.
274. General overview of the history of standardisation in the making and taking of psychotropic drugs. European Science Foundation Workshop on Standardizing Psychoactive Drugs and Drug Uses in the 20th Century. Utrecht April 2009.
275. Academic Stalking and Brand Fascism. York University, Toronto, Whistleblower Protection workshop, May 2009
276. The Future of Medical Care. Science and Technology Studies, Global Health Forum, University of California, Davis, May 2009.
277. Does anything stabilize moods? American Psychiatric Association Annual Meeting San Francisco May 2009

278. Psychedelic Psychopharmacotherapy: something old, something new?
Royal College of Psychiatrists, Annual Meeting June 2009
279. We're all Indian Now. Tracing Pharmaceuticals in South Asia Workshop,
Edinburgh, June 2009
280. Antidepressants and Violence. Broadmoor Hospital, Crowthorpe July
2009.
281. The Future of Medical Care, London Ontario, September 2009
282. Bioethical Devils and Neuroscientific Details. Halifax Bioethics September
2009
283. The Future of Medical Care. Grand Rounds, Dalhousie University, Sept
2009
284. The Future of Medical Care. Can Universal Healthcare Survive?
University of New Brunswick, Public Lecture, Fredericton, New Brunswick, Sept
2009.
285. Hearts & Minds. Antidepressants in Pregnancy. Fredericton, New
Brunswick, Sept 2009.
286. Hearts & Minds. The Risk from MotheRisk. U of Toronto, Oct 2009.
287. The Future of Medical Care. Festschrift for Ruth Kajander, U Western
Ontario, London, 2009.
288. The Politics of Evidence. 5th Annual Ronald Laing Lecture. Royal College
of Psychiatrists, London, October 2009.

Workshop/Training Programmes

When psychopharmacology goes wrong. Leading Edge Seminars, Toronto May 2002.

What a therapist needs to know about psychopharmacology. Centre for Training in Psychotherapy, April 23rd 2005, Toronto

When psychopharmacotherapy goes wrong. Leading Edge Seminars, Toronto, April 26th 2005

One of its outcomes was both the same. Statistical Methods in Psychopharmacology, Welsh Psychiatric Society, November 2005

Antidepressants & Homicide, RANZAPPL, Hunter Valley, April 10-11th 2006

How to recognised and deal with the hazards of psychotropic medication. Open Doors, U West of England, Bristol, February 27 2009.

The Marketing of Psychotropic Drugs, University of Minneapolis, May 2009.

In addition to the above, I have lectured in Departmental & Regional forums in

Bradford,
Bristol (x3),
Cardiff (x8),
Cambridge (x4),
Dumfries
Edinburgh (x2),
Wrexham (x2)
Glasgow
Leicester,
Leeds,
Maastricht,
Newcastle (x3),
Northampton
Norwich
Oxford,
Sheffield
St Bartholomew's,
The Clarke Institute Toronto (x4),
The Institute of Psychiatry (x3),
a number of Irish departmental settings,
on general practice training schemes in North Wales,
Royal College of Psychiatrists membership schemes in a number of locations,
& on several occasions to the Welsh Psychiatric Society.

I have also lectured in a variety of pharmaceutical company sponsored meetings throughout the UK (Newcastle, Glasgow, Cardiff, Bournemouth, Cambridge (x3), Merseyside (x3), London (x3)), as well as in Denmark, Greece (x2), Finland, Italy, Portugal, Spain (x2), Sweden, South Africa & at Satellite Symposia at major meetings such as ECNP & BAP.

Lectures for the most part in these latter forums have been on the history of the antidepressants or antipsychotics or on aspects of the methodologies for evaluating psychotropic efficacy.

I have lectured on a number of occasions for patient groups and for other professionals allied to mental health. Lectures to patient groups have included 3 annual guest lectures for MIND in North Wales.

I have also presented in forums such as the Café Scientifique in Leeds, Sept 1999, and again in November 2002, the British Association for the Advancement of Science, Imperial College, Sept 2000, and on a variety of media programmes dealing with aspects of mental health.

I have lectured at launch meetings for Organon in Athens, Pharmacia in Cambridge, Stockholm, Gothenburg, Malmo, Helsinki, Barcelona, Astra-Zeneca (Germany) in Cambridge, Pierre Fabre in Seoul and London, Astra Zeneca in Athens, Montreux and Seville, and Toronto for Janssen Pharmaceuticals.

I have been consulted on a range of programmes dealing with psychotropic drugs including File on Four, Panorama, Channel 4's The Secret History of Drugs, & Discovery TV's The Psychopharmacological Era, as well as CBC television and radio in Canada, including the Fifth Estate. I have also participated in a nationally broadcast debate on Australia's All in the Mind radio programme on issues surrounding the contemporary use of antidepressants, and participated in ABC in the US 20-20 and CBS programmes on hazards linked to the use of antidepressants.

SYMPOSIA & MEETINGS ORGANISED

I have organised Symposia for BAP Annual Meetings:

- In 1991 on Dementia: Biological Bases
- & Altered Consciousness: Phenomenology and Pharmacology
- In 1992 on: The Circadian System and Affective Disorders
- In 1993 on: Beyond the Receptor: The Significance of Gene Expression for Psychopharmacology
- In 1995 on: Social Phobia.
- In 1996 on: The Psychopharmacology of Aggression
- In 1997 on: Compliance and Psychopharmacology
- In 2000 on: Suicide and Psychotropic Treatment.
- In 2005 on: Dependence & Psychotropic Agents

The North Wales Regional Meeting of the BAP Spring 1992:

- Psychopharmacology: Big Business or Successful Science.
- Psychopharmacology in Primary Care

The BAP Winter Meeting 1993

- Psychotropic Drug Development: Social, Economic & Clinical Issues

A BAP Round-Table on Paediatric Psychopharmacology - London Jan 1997.

- This was attended by an international experts, regulators, the Royal Coll Psychiatrists and the pharmaceutical industry. I organised the meeting and wrote the resulting consensus statement.

For the Royal College of Psychiatrists (RCP)

I have organised a 1-day meeting & publication of proceedings in Sept 1989, on :
History of Biological Psychiatry

& Symposia for the RCP, Winter Meeting in Glasgow 1995 on:
The Relations between Psychiatry and the Pharmaceutical Industry

& for the Joint RCP & Assoc European Psychiatrists meeting in London 1996
on The History of Physical Treatments in Psychiatry

& a symposium for the 1998 CINP meeting in Glasgow on:
Neuropsychopharmacology: The Historical Record.

& for the Joint Royal College & World Psychiatric Assoc meeting in London 2001
on: The History of Drug Dependence

For the Int Assoc of Law & Mental Health:

When medical and legal worlds collide: SSRIs homicide and suicide Paris 2005

Homicide and Psychotropic Drugs: Padua 2007.

FORMAL TEACHING

In Galway, I taught on pharmacological and psychiatric topics in lecture, seminar and tutorial formats.

In Cambridge I gave lectures, tutorials and clinics to medical students and to candidates on Part I & II MRCPsych courses - covering schizophrenia, the affective disorders, psychopharmacology, substance abuse and the management and assessment of dementia. I was Asst. Tutor to Dr G Berrios for the MRCPsych and was involved in organising and assessing psychiatric and medical student training.

In N Wales, I train medical students from Cardiff and Liverpool, post-graduate psychiatric and GP trainees and contribute to paramedical training.

I have an Honorary appointment with the Dept. of Psychology in Bangor, where from 1990 to 1997 I lectured on abnormal psychology and the history of psychiatry.

I contribute to the College of Medicine's Diploma in Therapeutics, organised by Prof. Philip Routledge.

From 1990 to 2001, I organised a weekly multidisciplinary post-graduate training slot in Bangor with input from national and international guest lecturers.

From 1995 to the present I have organised an annual Guest Lecture slot with contributions from Edward Shorter, Richard Dawkins, Anthony Clare, Roy Porter, Simon Wessely, David Weatherall, David Goldberg & others.

I have lectured on the MRCPsych course for the U of Liverpool from 1997 to the present.

I organise and teach the psychopharmacology module for the U of Birmingham's Diploma in Community Mental Health

From 1992 through to the end of 1997, I was the S.R/Sp.R Programme Director in North Wales. During this time, the rotation expanded from three A.M.I and one learning disability post to seven A.M I and old age posts, one clinical lecturer post, two learning disability posts and there was always at least one research senior registrar. I have been the N Wales representative on the All-Wales Speciality Training Committee through the process of Calmanisation.

I was also the Audit Convenor in Gwynedd and the medical representative on the Clinical Effectiveness Committee from 1994 to 2001.

DEPARTMENTAL & UNIVERSITY DEVELOPMENT IN NORTH WALES

While Director of the North Wales Department of Psychological Medicine, the complement of Academic Staff increased from 2 Senior Lecturer posts to 4 Senior Lecturer posts, and later to 1 Chair and 3 other senior academic posts.

Structural problems became apparent in the course of the mid to late 1990s and these led me to push for and succeed in establishing a Chair in Psychological Medicine based at Wrexham, with links to the University of Wales Bangor. This is a post I did not compete for. In my judgement, at the time, both North Wales and the College of Medicine looked like being best served by a strategy that would involve attracting as many senior academics into North Wales as possible, a strategy that later became consistent with College of Medicine developments.

I have been personally responsible for the recruitment of all other academics in College of Medicine posts in psychiatry in North Wales.

DOCTORAL THESES SUPERVISED:

North West Wales has had no medical student and no formal post-graduate medical training during the period of time that I have been there. There have, furthermore, been no formal arrangements for collaborative research between the College of Medicine and the University of Wales Bangor.

Trainees on the psychiatric training scheme do not choose North Wales for research purposes. There have nevertheless been a relatively high number of trainees who have their names on articles and small though the numbers are there has been a greater proportion of trainees who have gone on to undertake higher research degrees than can be readily found elsewhere.

Dr C F Fear, MD. Cognitive Processes in Obsessive-Compulsive and Delusional Disorders. Awarded August 1995.

Dr B Williams, PhD. The Role of the Person in People Centred Mental Health Care. Awarded. November 1995.

Dr M-A Pasteur, PhD. The Role of Monoamine systems in Memory Functioning. Awarded. November 1995.

Dr R Tranter, PhD, The Role of Personality in Depressive Disorders and their Response to Antidepressants. Awarded December 2008

I currently have 2 whole-time research scientists working with me and I am supervising Paul Green & Margaret Harris in PhD programmes.

I have been an external PhD thesis examiner for:

University of London - psychiatry

University of London – psychology

University of New South Wales - history and philosophy of science

Lampeter University - philosophy of science

Brighton University – medical sociology

As well as external examiner for final MB exams at St Bartholomew's Hospital 1996-98.

& external examiner on the Aston University's Distance Learning Psychiatric Pharmacy Diploma & Certificate from 2002 – 2005.

PSYCHOTHERAPY

I have been the principal grant holder on a project investigating the efficacy of cognitive therapy for delusional disorders. Work in this area and contributions in two books led to an invitation to be keynote speaker on The Psychotherapy of the Psychoses at the thirtieth annual meeting of RANZCP in May of 1995.

Research is also in progress with R Bentall, J Day, A Rogers and others on behavioural determinants of compliance with neuroleptic medication with a view to constructing a management package aimed at enhancing compliance with treatment.

LEGAL WORK

I have been the medical expert for the NHS in a series of cases involving LSD therapy given in the 1950s and 1960s taken out against the NHS. These cases settled with a reputed saving to the NHS of several million pounds.

I have also advised the NHS litigation lawyers on pending ECT suits taken out against the NHS, and have given opinions on cases.

I have been instructed by the General Medical Council to offer a legal opinion on a case involving a matter of psychiatric interest.

I have also given medical opinions in a series of cases linked SSRI intake to suicide, violence, dependence and birth defects. These have in general discounted the role of medication in the claimed effects but in a small series of cases I have offered opinions for the claimants/defendants. These cases have led to a first ever verdict against a pharmaceutical company for psychiatric side effects of psychotropic medication. The case series has led to a Book – Let Them Eat Prozac, which aims at contributing original material to the more general debate on issues at the medico-legal interface.

I have been involved in one Canadian patent action, one securities case and more recently a series of cases centering on congenital malformations and their linkage to prenatal antidepressant intake.

INDUSTRIAL CONSULTANCIES:

Astra-Zeneca

Boots Pharmaceuticals

Eli Lilly

Janssen Pharmaceuticals

Lundbeck

Organon

Pharmacia-Upjohn

Rhone-Poulenc Rorer

SmithKline Beecham

CLINICAL SERVICE DEVELOPMENT

On arriving in North Wales, I established multidisciplinary working in a sectorised service. The clinical service I offer *ab initio* has had a number of interesting features, with patients having copies of all correspondence on them. This has been subject to a number of studies and has given rise to articles listed in the reference section. It has been highly praised by a number of service auditors and others.

Since 1997, I have been the lead consultant for ECT in North-West Wales and have established I believe the first full consultant led ECT service in the UK. All patients are seen by the ECT team prior to treatment, during treatment and subsequently following discharge, with consultant input on all ECT sessions.

Since 2002, I have had sessions devoted to the development of a liaison service with the general medical services in Bangor.

As a consequence for the past 5 years, I have been working from 5 to 8 fixed sessions.

Through 1990-94, I was Chairman of the Gwynedd group of psychiatric consultants. During this time, the psychiatric services moved from acute to community unit management and the North Wales psychiatric services adopted Trust status. By virtue of my position, I was centrally involved in developments.

At Directorate level:

- I have been recently reappointed the Chair of the Local Consultant group.
- I chair the Mental Health Clinical Governance Group.

On behalf of the North West Wales Trust:

- I sit on the Research Committee,
- & on the Clinical School Development Committee
- & I chair the Research Governance Review Committee;

This latter committee scrutinizes research for compliance with regulations such as the ionizing radiation regulations, human tissue act, capacity and consent, and for cost implications to the clinical service.

My clinical and academic input has been regularly cited as one reason why North West Wales has had all substantive and training posts filled in recent years, and why morale is particularly good in this service.